JP2749295B2 - High-molecular platinum complex compound, method for producing the same, and anticancer agent containing the same as an active ingredient - Google Patents
High-molecular platinum complex compound, method for producing the same, and anticancer agent containing the same as an active ingredientInfo
- Publication number
- JP2749295B2 JP2749295B2 JP8004602A JP460296A JP2749295B2 JP 2749295 B2 JP2749295 B2 JP 2749295B2 JP 8004602 A JP8004602 A JP 8004602A JP 460296 A JP460296 A JP 460296A JP 2749295 B2 JP2749295 B2 JP 2749295B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- platinum complex
- complex compound
- general formula
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title claims description 282
- 229910052697 platinum Inorganic materials 0.000 title claims description 87
- 150000001875 compounds Chemical class 0.000 title claims description 86
- 239000002246 antineoplastic agent Substances 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title claims description 13
- 239000004480 active ingredient Substances 0.000 title claims description 3
- 229920000642 polymer Polymers 0.000 claims description 69
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 63
- -1 ammonium ions Chemical class 0.000 claims description 35
- 102100028735 Dachshund homolog 1 Human genes 0.000 claims description 32
- 101000915055 Homo sapiens Dachshund homolog 1 Proteins 0.000 claims description 32
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 claims description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 22
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 21
- 239000002244 precipitate Substances 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 17
- 239000011734 sodium Substances 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 150000001412 amines Chemical class 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 229910052783 alkali metal Inorganic materials 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- UYBWIEGTWASWSR-UHFFFAOYSA-N 1,3-diaminopropan-2-ol Chemical compound NCC(O)CN UYBWIEGTWASWSR-UHFFFAOYSA-N 0.000 claims description 6
- 229910002651 NO3 Inorganic materials 0.000 claims description 6
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- HFAYPKGISTWLIZ-UHFFFAOYSA-N [4-(aminomethyl)oxan-4-yl]methanamine Chemical compound NCC1(CN)CCOCC1 HFAYPKGISTWLIZ-UHFFFAOYSA-N 0.000 claims description 4
- 229910001413 alkali metal ion Inorganic materials 0.000 claims description 4
- JINBYESILADKFW-UHFFFAOYSA-N aminomalonic acid Chemical compound OC(=O)C(N)C(O)=O JINBYESILADKFW-UHFFFAOYSA-N 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 150000004985 diamines Chemical class 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 239000011541 reaction mixture Substances 0.000 claims description 4
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 claims description 2
- DDHUNHGZUHZNKB-UHFFFAOYSA-N 2,2-dimethylpropane-1,3-diamine Chemical compound NCC(C)(C)CN DDHUNHGZUHZNKB-UHFFFAOYSA-N 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- SEWIYICDCVPBEW-BYPYZUCNSA-N L-glutamate methyl ester Chemical compound COC(=O)[C@@H](N)CCC(O)=O SEWIYICDCVPBEW-BYPYZUCNSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 229910052788 barium Inorganic materials 0.000 claims description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- BLOXTRRBJWXTGT-UHFFFAOYSA-N cyclobutylmethanediamine Chemical compound NC(N)C1CCC1 BLOXTRRBJWXTGT-UHFFFAOYSA-N 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 125000004494 ethyl ester group Chemical group 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 claims description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims 1
- GZEYLLPOQRZUDF-UHFFFAOYSA-N 7-(dimethylamino)-4-methylchromen-2-one Chemical compound CC1=CC(=O)OC2=CC(N(C)C)=CC=C21 GZEYLLPOQRZUDF-UHFFFAOYSA-N 0.000 claims 1
- 102100021792 Gamma-sarcoglycan Human genes 0.000 claims 1
- 101000616435 Homo sapiens Gamma-sarcoglycan Proteins 0.000 claims 1
- 150000008043 acidic salts Chemical class 0.000 claims 1
- 150000001447 alkali salts Chemical class 0.000 claims 1
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 45
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 36
- 238000000921 elemental analysis Methods 0.000 description 36
- 239000001257 hydrogen Substances 0.000 description 36
- 229910052739 hydrogen Inorganic materials 0.000 description 36
- 238000002329 infrared spectrum Methods 0.000 description 36
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 36
- 238000003786 synthesis reaction Methods 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 18
- 229960004316 cisplatin Drugs 0.000 description 18
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 18
- 230000001093 anti-cancer Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 7
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940041181 antineoplastic drug Drugs 0.000 description 6
- 239000006227 byproduct Substances 0.000 description 6
- 229960004562 carboplatin Drugs 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- NPHRGEZGUMJYJH-UHFFFAOYSA-N [Pt].[I] Chemical compound [Pt].[I] NPHRGEZGUMJYJH-UHFFFAOYSA-N 0.000 description 3
- GLFVNTDRBTZJIY-UHFFFAOYSA-N diethyl 2-aminopropanedioate;hydron;chloride Chemical compound Cl.CCOC(=O)C(N)C(=O)OCC GLFVNTDRBTZJIY-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 3
- QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- MMVUZMIOJNPDME-UHFFFAOYSA-N 4-methylbenzenesulfonate;triethylazanium Chemical compound CC[NH+](CC)CC.CC1=CC=C(S([O-])(=O)=O)C=C1 MMVUZMIOJNPDME-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910021612 Silver iodide Inorganic materials 0.000 description 2
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 2
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 2
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 2
- 150000003057 platinum Chemical class 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 235000010344 sodium nitrate Nutrition 0.000 description 2
- 239000004317 sodium nitrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- GYVXJNQPQQGGCZ-UHFFFAOYSA-N 2,2-bis(aminomethyl)propane-1,3-diol Chemical compound NCC(CN)(CO)CO GYVXJNQPQQGGCZ-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229910001422 barium ion Inorganic materials 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- UBIJTWDKTYCPMQ-UHFFFAOYSA-N hexachlorophosphazene Chemical compound ClP1(Cl)=NP(Cl)(Cl)=NP(Cl)(Cl)=N1 UBIJTWDKTYCPMQ-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229920000592 inorganic polymer Polymers 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- DJXYWDRBAAVVSG-UHFFFAOYSA-J potassium;tetrachloroplatinum Chemical compound [K].Cl[Pt](Cl)(Cl)Cl DJXYWDRBAAVVSG-UHFFFAOYSA-J 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 229940045105 silver iodide Drugs 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- ORXDFZVXVSSTPU-UHFFFAOYSA-J tetrapotassium tetrachloride Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[K+].[K+].[K+].[K+] ORXDFZVXVSSTPU-UHFFFAOYSA-J 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F17/00—Metallocenes
- C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Description
【0001】[0001]
【発明の属する技術分野】本発明は、新規の高分子白金
錯化合物誘導体、その製造方法及び抗ガン剤に関する。
さらに詳しくは、ポリホスファゼン(polyphosphazene)
に導入された調節放出型白金錯化合物誘導体、その製造
方法及び抗ガン剤に関する。TECHNICAL FIELD The present invention relates to a novel high-molecular platinum complex compound derivative, a method for producing the same, and an anticancer agent.
For more information, see Polyphosphazene
The present invention relates to a controlled-release platinum complex compound derivative introduced into a compound, a method for producing the same, and an anticancer agent.
【0002】[0002]
【従来の技術】現在使われている抗ガン剤のうち、白金
系列錯化合物誘導体であるシスプラチン(cisplatin)、
すなわちcis−(NH3)2 PtCl2 は、1965年
に米国のB. Rosenberg, Nature 205, 698 (1965)により
その抗ガン効果が明らかにされ、1979年に米国のF
DAから抗ガン剤として正式に許可され、睾丸ガン、卵
巣ガン、膀胱ガン、喉頭ガンなど種々のガンに対して最
も効果的な化学療法剤として使われている。しかし、強
い毒性(LD50=13mg/kg 、M.J. Cleare, Biochimie
60, 835 (1978))のため、その使用は制限されているの
が現状である。一方、1989年にFDAから許可さ
れ、最近第2世代抗ガン剤として使われ始めたカルボプ
ラチン、すなわちcis−(NH3)2 Pt(CBDC
A)(CBDCA=1,1−シクロブタンジカルボン酸
塩)は、毒性(LD50=180mg/kg 、M.J. Cleare, B
iochimie 60, (1978))がシスプラチンより遥かに低い
が、抗ガン効果と治療可能なガンの範囲がシスプラチン
に比べて狭く、高価であるのでやはり幅広く使われてい
ない。したがって、シスプラチン以上に抗ガン効果が優
れ、毒性の低い第3世代抗ガン剤を見出す研究が世界的
に活発に進められており、この研究報告は一々列挙でき
ないほど多数である。しかし、商品化においては、成功
段階には至っていない。第3世代白金錯化合物が抗ガン
剤として揃えるべき条件は、シスプラチン以上の優秀な
抗ガン効果を有し、カルボプラチン程度に毒性が低く、
シスプラチン又はカルボプラチン耐性ガン細胞に対して
も効果が優れ、交差耐性(cross-resisitance)がなく、
治療可能なガン細胞の領域がさらに広くなければならな
いなどである。また、薬物の水に対する溶解度が高く、
化学的に安定であるなど種々の条件を満たさなければな
らないので、現在世界的に臨床試験中の候補化合物は、
10種類ほどあるが、商品化にはまだ成功していない。2. Description of the Related Art Among anticancer drugs currently used, cisplatin, which is a derivative of a platinum series complex compound,
That is, cis- (NH 3 ) 2 PtCl 2 was found to have an anticancer effect by B. Rosenberg, Nature 205 , 698 (1965) in the United States in 1965, and F.S.
It has been officially approved by the DA as an anticancer agent and is used as the most effective chemotherapeutic agent for various cancers such as testicular cancer, ovarian cancer, bladder cancer, and laryngeal cancer. However, strong toxicity (LD 50 = 13 mg / kg, MJ Cleare, Biochimie
60 , 835 (1978)), and its use is currently restricted. On the other hand, carboplatin, which was approved by the FDA in 1989 and has recently started to be used as a second-generation anticancer drug, namely cis- (NH 3 ) 2 Pt (CBDC
A) (CBDCA = 1,1-cyclobutanedicarboxylate) is toxic (LD 50 = 180 mg / kg, MJ Cleare, B
Although iochimie 60 , (1978)) is much lower than cisplatin, it is still not widely used because of its narrower and more expensive anticancer effects and the range of treatable cancers than cisplatin. Therefore, research for finding a third-generation anticancer drug having a superior anticancer effect and lower toxicity than cisplatin has been actively pursued worldwide, and this research report is too numerous to enumerate individually. However, commercialization has not reached a successful stage. The conditions under which the third-generation platinum complex compound should be prepared as an anticancer agent have excellent anticancer effect more than cisplatin, low toxicity as low as carboplatin,
Excellent effect on cisplatin or carboplatin-resistant cancer cells, no cross-resisitance,
The area of cancer cells that can be treated must be larger. In addition, the solubility of the drug in water is high,
Since various conditions must be satisfied, such as being chemically stable, candidate compounds currently undergoing clinical trials worldwide include:
There are about 10 types, but they have not been commercialized yet.
【0003】シスプラチン錯化合物の抗ガン作用及び毒
性はまだ確実に解明されていないが、今までの研究結果
を簡単に説明すると、Pharmac. Ther. 25, 297-326 (19
84);Chem. Rev. 87, 1153-1181 (1987)に発表されてい
るように、シスプラチンが注射などにより血中に投与さ
れると、一部は加水分解を起こすが、血中塩素イオン濃
度(〜100mM)が高いため、ほとんどはイオン化され
ずに中性分子として存在して、細胞膜を通って拡散す
る。細胞内では塩素イオン濃度(4mM)が低いので、ほ
とんどの塩素イオンが加水分解により除去され、アミン
−白金陽イオンが、細胞の主要構成成分であるDNAと
結合して、DNAの複製を妨害することにより殺細胞効
果を示す。このとき、白金錯化合物は、正常細胞とガン
細胞とを区分することができないので、細胞毒性を示
し、シスプラチンの加水分解により生成されたオリゴマ
ーも体内で種々の毒性を示すと理解されている。しか
し、シスプラチン分子内のアミン中性リガンドと陰イオ
ンの分子構造が、抗ガン活性や体内毒性に及ぼす具体的
な関係については未だ解明されていない。Although the anticancer activity and toxicity of cisplatin complex compounds have not yet been elucidated yet, the results of the studies so far can be briefly described as Pharmac. Ther. 25 , 297-326 (19)
84); as published in Chem. Rev. 87 , 1153-1181 (1987), when cisplatin is administered to the blood by injection or the like, a part of it undergoes hydrolysis, but blood chloride ion concentration Due to their high (〜100 mM), most exist as neutral molecules without ionization and diffuse through cell membranes. Since chloride concentration (4 mM) is low in cells, most chloride ions are removed by hydrolysis, and amine-platinum cations bind to DNA, which is a major component of cells, and interfere with DNA replication. Thus, a cell killing effect is exhibited. At this time, it is understood that the platinum complex compound cannot differentiate between normal cells and cancer cells, and thus exhibits cytotoxicity, and oligomers formed by hydrolysis of cisplatin also exhibit various toxicity in the body. However, the specific relationship between the molecular structure of the amine neutral ligand and the anion in the cisplatin molecule on anticancer activity and internal toxicity has not yet been elucidated.
【0004】[0004]
【課題を解決するための手段】本発明者らは、既存のシ
スプラチンより抗ガン効果が優れており、毒性の低い新
たな第3世代白金系列抗ガン剤を開発するために集中的
に研究した結果、生体分解性無機高分子であるポリホス
ファゼン系高分子鎖に、溶解性を付与する基及びアミノ
ジカルボン酸誘導体を導入した後、加水分解を経てアミ
ノジカルボン酸にシスプラチン系白金錯化合物を結合さ
せて製造した、後記の一般式(I)の高分子型白金錯化
合物が、シスプラチンよりはるかに優れた抗ガン効果を
有し、その毒性はカルボプラチンと同程度に低く、特に
シスプラチン耐性ガン細胞に対する抗ガン効果が優れて
いるのみならず、既存のシスプラチンで治療し難い肺ガ
ン、胃ガン、腸ガン細胞に対しても、優れた抗ガン効果
を示すことを見出した。これは、高分子鎖に白金系列抗
ガン剤を導入した本発明の薬剤を体内に投与する場合、
高分子鎖から白金錯化合物の有効成分が調節して放出さ
れ、薬物の適正有効濃度が一定時間保たれることによ
り、低毒性と優れた抗ガン効果が示されるものと考えら
れる。DISCLOSURE OF THE INVENTION The present inventors have intensively studied to develop a new third-generation platinum-series anticancer drug which has better anticancer effect than existing cisplatin and has low toxicity. As a result, after introducing a group imparting solubility and an aminodicarboxylic acid derivative to a polyphosphazene-based polymer chain that is a biodegradable inorganic polymer, the cisplatin-based platinum complex compound is bonded to the aminodicarboxylic acid via hydrolysis. The high molecular weight platinum complex compound of the following general formula (I) produced by the above method has a much better anticancer effect than cisplatin, and its toxicity is as low as carboplatin, especially against cisplatin-resistant cancer cells. Not only has excellent cancer effect, but also has excellent anticancer effect against lung, stomach and intestinal cancer cells that are difficult to treat with existing cisplatin It was. This is because when the drug of the present invention in which a platinum series anticancer drug is introduced into the polymer chain is administered into the body,
It is considered that the active ingredient of the platinum complex compound is controlled and released from the polymer chain, and the appropriate effective concentration of the drug is maintained for a certain period of time, thereby exhibiting low toxicity and excellent anticancer effect.
【0005】本発明は、次の一般式(I)で示される、
抗ガン効果が優秀な、新規の、ポリホスファゼンに導入
された高分子白金錯化合物誘導体及びその製造方法に関
する。The present invention provides a compound represented by the following general formula (I):
The present invention relates to a novel polymer platinum complex compound derivative introduced into polyphosphazene, which has an excellent anticancer effect, and a method for producing the same.
【0006】[0006]
【化3】 Embedded image
【0007】〔式中、高分子骨格は、P=N反復単位を
有するポリホスファゼンを基体とし、Sは、溶解性を付
与する基であって、ヒドロキシル基、又はメトキシ、エ
トキシ、(2−メトキシ)エトキシのようなアルコキシ
基、又はメチルアミノ、ジメチルアミノのようなアルキ
ルアミノ基を示し; Aは、一座中性リガンドのアンモニア、又はメチルアミ
ン、エチルアミンのように1〜3個の炭素原子を有する
アルキルアミンもしくはシクロプロピルアミン(CP
A)を示すか、あるいはエチレンジアミン(en)、プ
ロピレンジアミン(pn)、2−ヒドロキシ−1,3−
ジアミノプロパン(HDAP)、2,2−ジメチル−
1,3−ジアミノプロパン(DMDAP)、1,1−ジ
アミノメチルシクロブタン(DAMCB)、テトラヒド
ロ−4H−ピラン−4,4−ジメタンアミン(THPD
MA)、2,2−ビスアミノメチル−1,3−プロパン
ジオール(BAMPDO)及びトランス−1,2−ジア
ミノシクロヘキサン(DACH)から選ばれる2個のア
ミンが一緒になったA−A型のキレート型アミンを形成
し; xは、整数0、1又は2を示し、アミノジカルボン酸の
陰イオン部分は、アミノジカルボン酸の種類に応じて、
x=0のときはアミノマロン酸(Am)誘導体、x=1
のときはアスパラギン酸(Asp)誘導体、x=2のと
きはグルタミン酸(Glt)誘導体を示し; Mは、ナトリウムイオン(Na+)、カリウムイオン(K
+)のような2個のアルカリ金属イオン又は2個のアンモ
ニウムイオンを示すか、あるいはカルシウムイオン(C
a2+)、バリウムイオン(Ba2+)のような1個のアル
カリ土類金属イオンを示し; 白金錯体の含量を示すm値は、0.2ないし1であり、
ポリホスファゼンの重合度を示すn値は、10ないし1
00である。〕Wherein the polymer skeleton is based on a polyphosphazene having P = N repeating units, and S is a group imparting solubility and is a hydroxyl group or methoxy, ethoxy, (2-methoxy A) represents an alkoxy group such as ethoxy, or an alkylamino group such as methylamino, dimethylamino; A is a monodentate neutral ligand ammonia, or has 1 to 3 carbon atoms such as methylamine, ethylamine Alkylamine or cyclopropylamine (CP
A) or ethylenediamine (en), propylenediamine (pn), 2-hydroxy-1,3-
Diaminopropane (HDAP), 2,2-dimethyl-
1,3-diaminopropane (DMDAP), 1,1-diaminomethylcyclobutane (DAMCB), tetrahydro-4H-pyran-4,4-dimethanamine (THPD)
MA), AA type chelate obtained by combining two amines selected from 2,2-bisaminomethyl-1,3-propanediol (BAMPDO) and trans-1,2-diaminocyclohexane (DACH) X represents an integer 0, 1 or 2 and the anionic portion of the aminodicarboxylic acid, depending on the type of aminodicarboxylic acid,
When x = 0, aminomalonic acid (Am) derivative, x = 1
Represents an aspartic acid (Asp) derivative, x = 2 represents a glutamic acid (Glt) derivative; M represents a sodium ion (Na + ), a potassium ion (K
+ ) Indicates two alkali metal ions or two ammonium ions such as calcium ion (C
a 2+ ), one alkaline earth metal ion such as barium ion (Ba 2+ ); m value indicating the content of the platinum complex is 0.2 to 1,
The n value indicating the degree of polymerization of polyphosphazene is 10 to 1
00. ]
【0008】本発明による、白金錯化合物がポリホスフ
ァゼン鎖に導入された、前記一般式(I)の高分子白金
錯化合物は、新規物質であって、優秀な抗ガン効果と優
秀な性質を示すことが認められた。The high molecular weight platinum complex compound of the formula (I) wherein the platinum complex compound is introduced into the polyphosphazene chain according to the present invention is a novel substance and has excellent anticancer effect and excellent properties. It was recognized that.
【0009】本発明による、一般式(I)のポリホスフ
ァゼンに導入された白金錯化合物誘導体の製造方法を、
以下に簡単に説明する。According to the present invention, there is provided a process for producing a platinum complex compound derivative introduced into a polyphosphazene of the general formula (I),
This will be briefly described below.
【0010】すなわち、ポリジクロロホスファゼンに、
白金錯化合物連結剤であるアミノジカルボン酸誘導体と
溶解性を付与する基とを導入した後、加水分解工程を経
て一般式(II)のアンモニウム塩もしくはアルカリ金属
塩又は一般式(III)のアルカリ土類金属塩を得、一般式
(II)又は一般式(III)の化合物と一般式(IV)のジア
ミン白金酸性塩を、1:0.2〜1のモル比で、常温の
水溶液中で反応させることにより、一般式(I)の高分
子白金錯化合物が得られる。That is, polydichlorophosphazene has
After introducing an aminodicarboxylic acid derivative as a platinum complex compound linking agent and a group for imparting solubility, a hydrolysis step is carried out, and then an ammonium salt or an alkali metal salt of the general formula (II) or an alkaline earth of the general formula (III) A metal salt is obtained, and the compound of the general formula (II) or (III) is reacted with the diamine platinum acid salt of the general formula (IV) in a molar ratio of 1: 0.2 to 1 in an aqueous solution at room temperature. By doing so, a polymer platinum complex compound of the general formula (I) is obtained.
【0011】[0011]
【化4】 Embedded image
【0012】〔上記式中、S、A、x、M、m及びn
は、前記で定義されたとおりであり、M(I)は、アン
モニウムイオン又はアルカリ金属イオンを示し、M(I
I)は、アルカリ土類金属イオンを示し、X2 は、陰イ
オンであって、2個のNO3 -イオン、又は1個のSO4
2- イオンを示す。〕[Where S, A, x, M, m and n
Is as defined above, M (I) represents an ammonium ion or an alkali metal ion, and M (I
I) represents an alkaline earth metal ion, X 2 is an anion, and is composed of two NO 3 − ions or one SO 4
Shows 2- ions. ]
【0013】一般式(IV)のアミン−白金水溶性酸性塩
は、一般式(V)のアミン白金ヨウ素と、銀の水溶性酸
性塩を文献(R.C. Harrison, Inorg. Chimica Acta 46,
L15(1980))記載の方法によりそれぞれ反応させること
によって製造することができる。The amine-platinum water-soluble acid salt of the general formula (IV) can be obtained from the amine platinum iodine of the general formula (V) and a water-soluble acid salt of silver in the literature (RC Harrison, Inorg. Chimica Acta 46 ,
L15 (1980)).
【0014】[0014]
【化5】 Embedded image
【0015】一般式(V)において、Aは、一般式
(I)で定義されたとおりである。一般式(V)のアミ
ン白金ヨウ素は、四塩化白金カリウムとヨウ化カリウム
及びアミン化合物を、文献(M.J. Cleare, Biochimie 6
0, 835 (1978))記載の方法により反応させれば容易に得
られる。In the general formula (V), A is as defined in the general formula (I). The amine platinum iodine of the general formula (V) can be obtained by combining potassium tetrachloride, potassium iodide, and an amine compound with the reference (MJ Cleare, Biochimie 6).
0 , 835 (1978)).
【0016】本発明の一般式(I)で示される高分子白
金錯化合物誘導体の製造方法を具体的に説明する。まず
白金錯化合物を導入する高分子骨格であるポリホスファ
ゼンを合成し、この高分子骨格に溶解性を付与する基及
び白金錯化合物連結剤を導入し、そして最終的に白金錯
化合物を導入する3段階に区分できる。The method for producing the polymer platinum complex compound derivative represented by the general formula (I) of the present invention will be specifically described. First, a polyphosphazene, which is a polymer skeleton for introducing a platinum complex compound, is synthesized, a group imparting solubility to the polymer skeleton and a platinum complex compound linking agent are introduced, and finally, a platinum complex compound is introduced. It can be divided into stages.
【0017】まず、ポリホスファゼンの合成は、常法
(例:Macromolecule, 8, 36 (1975))によりホスファゼ
ン3量体、すなわち(N=PCl2)3 を熱重合させてポ
リジクロロホスファゼン線形重合体、すなわち(N=P
Cl2)n を得ることからなる。この重合体を、無水ベン
ゼン、トルエン、テトラヒドロフラン又はジオキサン溶
媒中に、塩化水素除去剤として過剰量のトリエチルアミ
ンと共に溶解する。この溶液を、白金錯化合物連結剤と
して2個のカルボキシル基を有するアミノ酸であるアミ
ノマロン酸、アスパラギン酸もしくはグルタミン酸のメ
チルエステル、エチルエステル、ベンジルエステル又は
アルキルアミドを、前記ホスファゼン重合体の単位分子
と同等のモル比で溶媒に溶解した溶液に徐々に加えた
後、5〜10時間常温で撹拌する。沈殿したトリエチル
アミン塩酸塩を濾過した後、濾過液に、溶解性を付与す
る基を導入する試薬として水、又はメタノール、エタノ
ール、メトキシエタノールのような水溶性アルコール、
又はメチルアミン、エチルアミンのような水溶性アミン
と共にトリエチルアミンを同等のモル比で加えた後、再
び2〜10時間常温で撹拌し、必要に応じて還流する。
こうして得た、アミノ酸と溶解性を付与する基が共に置
換された重合体を含む反応物を、過剰量のn−ヘキサン
に注ぐと、ほとんどの重合体が沈殿する。ヘキサン溶液
を濾過して得た沈殿重合体をテトラヒドロフランやジオ
キサンのような極性溶媒に再び溶解した後、蒸留水に注
いで重合体を沈殿させる精製過程を2〜3回繰り返す。
このように精製した重合体を、アルコール−テトラヒド
ロフランの共溶媒に再び溶解した後、この溶液に、置換
アミノ酸に対して1.0〜1.5当量のナトリウム、カ
リウムのようなアルカリ金属の水酸化物又はカルシウ
ム、バリウムのようなアルカリ土類金属の水酸化物を溶
解した後、常温で2〜10時間撹拌して加水分解させる
ことによって、前記一般式(II)又は一般式(III)の水
溶性アミノ酸金属塩を沈殿させる。この沈殿物を濾過し
てアルコールやアセトンで十分に洗浄して乾燥した後、
次のようにアミン白金錯化合物中間体と反応させる。First, polyphosphazene is synthesized by a conventional method (eg, Macromolecule, 8 , 36 (1975)), which is obtained by thermally polymerizing a phosphazene trimer, ie, (N = PCl 2 ) 3 , to obtain a polydichlorophosphazene linear polymer. , That is, (N = P
Cl 2 ) n . The polymer is dissolved in anhydrous benzene, toluene, tetrahydrofuran or dioxane solvent with excess triethylamine as a hydrogen chloride scavenger. This solution is prepared by combining aminomalonic acid, aspartic acid or glutamic acid methyl ester, ethyl ester, benzyl ester or alkylamide, which is an amino acid having two carboxyl groups, as a platinum complex compound linking agent with the unit molecule of the phosphazene polymer. After gradually adding to the solution dissolved in the solvent in the same molar ratio, the mixture is stirred at room temperature for 5 to 10 hours. After filtering the precipitated triethylamine hydrochloride, the filtrate is water or a water-soluble alcohol such as methanol, ethanol, or methoxyethanol as a reagent for introducing a group imparting solubility,
Alternatively, after adding triethylamine in an equivalent molar ratio together with a water-soluble amine such as methylamine or ethylamine, the mixture is again stirred at room temperature for 2 to 10 hours, and refluxed if necessary.
When the thus obtained reaction product containing a polymer in which both the amino acid and the group imparting solubility are substituted is poured into an excessive amount of n-hexane, most of the polymer precipitates. A purification process in which the precipitated polymer obtained by filtering the hexane solution is redissolved in a polar solvent such as tetrahydrofuran or dioxane and then poured into distilled water to precipitate the polymer is repeated two to three times.
The polymer thus purified is redissolved in a co-solvent of alcohol-tetrahydrofuran, and the solution is added with 1.0 to 1.5 equivalents of an alkali metal such as sodium or potassium based on the substituted amino acid. Or a hydroxide of an alkaline earth metal such as calcium or barium, and then hydrolyzing by stirring at room temperature for 2 to 10 hours to obtain the aqueous solution of the general formula (II) or the general formula (III). Precipitate the amino acid metal salt. This precipitate is filtered, washed thoroughly with alcohol or acetone, and dried,
The reaction with the amine platinum complex intermediate is carried out as follows.
【0018】すなわち、四塩化白金カリウムの水溶液に
過剰量のヨウ化カリウムを反応させた後、所望のアミン
(A)2当量と水溶液中で反応させて、一般式(V)の
アミン白金ヨウ素中間体を文献記載の方法により得た
後、これに、銀の水溶性酸性塩、すなわち硝酸銀や硫酸
銀の同当量を加え、常温で2〜10時間撹拌するとヨウ
化銀が沈殿し、一般式(IV)の水溶性アミン白金酸性塩
が得られる。こうして得たアミン白金酸性塩の水溶液
と、上記で得た一般式(II)のポリホスファゼンのアミ
ノ酸アルカリ金属塩又は一般式(III)のアルカリ土類金
属塩の水溶液を、0.2〜1:1のモル比で水溶液中撹
拌することによって、相互交換反応により一般式(I)
のポリホスファゼンのアミノ酸白金錯化合物が形成さ
れ、副産物としてアルカリ金属もしくはアルカリ土類金
属の硝酸塩又は硫酸塩が生成する。このように副産物と
して得られる硝酸塩又は硫酸塩は、前記反応溶液を半透
膜(分子量1,000以下通過)製容器に入れ、蒸留水
で10〜24時間透析するか、反応溶液中のポリホスフ
ァゼン白金錯化合物と、副産物である硝酸塩又は硫酸塩
との溶解度の差を用いて分離精製することができる。例
えば、ポリホスファゼンのアミノ酸アルカリ土類金属塩
とアミン白金の硫酸塩を反応させる場合、アルカリ土類
金属の硫酸塩は水に溶けにくいので沈殿し、ポリホスフ
ァゼンのアミノ酸白金錯化合物のみが水に溶けるので、
これを濾過分離すればよい。そして、ポリホスファゼン
のアミノ酸アルカリ金属塩をアミン白金の硝酸塩と反応
させる場合、硝酸カリウム又は硝酸ナトリウムが副産さ
れるが、これらの水に対する溶解度は大きいので、反応
溶液中にポリホスファゼンのアミノ酸白金錯化合物と共
存する。しかし、硝酸ナトリウムや硝酸カリウムはアル
コールに溶け、白金錯化合物はほとんど溶けないため、
水/アルコール溶媒を用いて分離することができる。ま
た、ポリホスファゼンのアミノ酸ナトリウム又はカリウ
ム塩とアミン白金硫酸塩とを反応させる場合、副産物の
硫酸ナトリウム又は硫酸カリウムは水溶性であるため、
水/アセトン溶媒を用いれば容易に分離精製することが
できる。このような一般式(I)の製造方法を反応式で
示すと次のとおりである。That is, an excess amount of potassium iodide is reacted with an aqueous solution of potassium platinum tetrachloride, and then reacted with 2 equivalents of a desired amine (A) in an aqueous solution to obtain an amine platinum iodine intermediate of the general formula (V). After obtaining the product by the method described in the literature, a water-soluble acid salt of silver, that is, the same equivalent of silver nitrate or silver sulfate is added thereto, and the mixture is stirred at room temperature for 2 to 10 hours to precipitate silver iodide. A water-soluble amine platinum acid salt of IV) is obtained. The aqueous solution of the amine platinum acid salt thus obtained and the aqueous solution of the amino acid alkali metal salt of polyphosphazene of the general formula (II) or the alkaline earth metal salt of the general formula (III) obtained above were mixed with 0.2 to 1: By stirring in an aqueous solution at a molar ratio of 1 to obtain a compound of the general formula (I)
Is formed, and a nitrate or a sulfate of an alkali metal or an alkaline earth metal is produced as a by-product. The nitrate or sulfate thus obtained as a by-product can be obtained by placing the reaction solution in a container made of a semipermeable membrane (passing a molecular weight of 1,000 or less) and dialyzing with distilled water for 10 to 24 hours, or polyphosphazene in the reaction solution. Separation and purification can be performed using the difference in solubility between the platinum complex compound and the by-product nitrate or sulfate. For example, when reacting an amino acid alkaline earth metal salt of polyphosphazene with an amine platinum sulfate, the alkaline earth metal sulfate is hardly soluble in water, so that it precipitates, and only the polyphosphazene amino acid platinum complex compound is soluble in water. So
This may be separated by filtration. When reacting an amino acid alkali metal salt of polyphosphazene with a nitrate of amine platinum, potassium nitrate or sodium nitrate is produced as a by-product, but since these have high solubility in water, the amino acid platinum complex compound of polyphosphazene is contained in the reaction solution. Coexist with However, sodium nitrate and potassium nitrate are soluble in alcohol, and platinum complex compounds are almost insoluble.
Separation can be achieved using a water / alcohol solvent. Further, when reacting the amino acid sodium or potassium salt of polyphosphazene with the amine platinum sulfate, since sodium sulfate or potassium sulfate as a by-product is water-soluble,
If a water / acetone solvent is used, separation and purification can be easily performed. The production method of the general formula (I) is represented by the following reaction formula.
【0019】[0019]
【化6】 Embedded image
【0020】[0020]
【実施例】次に実施例を挙げて本発明をさらに詳しく説
明するが、本発明はこれらの実施例に限定されるもので
はない。EXAMPLES The present invention will be described in more detail with reference to the following examples, but the present invention is not limited to these examples.
【0021】実施例1{NP(OH)〔Asp・Pt(DACH)〕0.9(As
p・K2)0.1・2H2O }n の合成 ヘキサクロロシクロトリホスファゼン〔(N=PCl
2 )3 〕3.0g(8.63mmol)と無水塩化アルミニウ
ム0.30g(2.25mmol)を、220mm×23mmパイ
レックスアンプルに入れ、密封した後、1rpm で回転さ
せながら250℃で2時間反応させ、ポリジクロロホス
ファゼンを合成した。アンプルを室温で冷却した後、ア
ルゴン気流下、ドライボックス中で開封し、生成物を、
精製無水THFに溶解し、溶液をそのまま置換反応に使
った。L−アスパルトイルジベンジルエステル−p−ト
ルエンスルホン酸塩13.2g(27.2mmol)をTHF
400mlに加え、0℃に冷却し、トリエチルアミン7.
56ml(54.4mmol)を加えて30分間撹拌した。こ
れに、先に合成しておいたポリジクロロホスファゼン
3.0g が溶解しているTHF溶液150mlを1時間か
けて滴下し、室温で20時間撹拌した。このときに生成
した沈殿物(Et3 N・HCl及びトリエチルアンモニ
ウム−p−トルエンスルホン酸塩)を濾過した濾過液
に、トリエチルアミン3.78ml(27.2mmol)と水
0.49ml(27.2mmol)を入れ、室温で12時間撹
拌した。このときに、再び生成した沈殿物(Et3 N・
HCl)を濾過した後、濾過液を30℃で減圧蒸留して
得た生成物を再びTHFに溶解した後、過剰量のn−ヘ
キサンに滴下して白色の沈殿物を得、再びこの沈殿物を
THFに溶解した後、過剰量の蒸留水に滴下し、得た白
色の重合体〔NP(OH)(L−Asp・(CH2 P
h)2) 〕n を減圧乾燥した(収率:85%)。Example 1 ΔNP (OH) [Asp.Pt (DACH)] 0.9 (As
p · K 2 ) Synthesis of 0.1 · 2H 2 O} n Hexachlorocyclotriphosphazene [(N = PCl
2 ) 3 ] 3.0 g (8.63 mmol) of anhydrous aluminum chloride and 0.30 g (2.25 mmol) of anhydrous aluminum chloride were placed in a 220 mm × 23 mm Pyrex ampule, sealed, and reacted at 250 ° C. for 2 hours while rotating at 1 rpm. And polydichlorophosphazene. After cooling the ampoule at room temperature, it was opened in a dry box under a stream of argon and the product was
It was dissolved in purified anhydrous THF, and the solution was used for the substitution reaction as it was. 13.2 g (27.2 mmol) of L-aspartoyl dibenzyl ester-p-toluenesulfonate was added to THF.
6. Add 400 ml, cool to 0 ° C., and triethylamine
56 ml (54.4 mmol) was added and stirred for 30 minutes. To this, 150 ml of a THF solution in which 3.0 g of the previously synthesized polydichlorophosphazene was dissolved was added dropwise over 1 hour, followed by stirring at room temperature for 20 hours. Precipitate formed at this time to (Et 3 N · HCl and triethylammonium -p- toluenesulfonate) filtrate was filtered, triethylamine 3.78 ml (27.2 mmol) and water 0.49 ml (27.2 mmol) And stirred at room temperature for 12 hours. At this time, the precipitate (Et 3 N ·
HCl) was filtered, the filtrate was distilled under reduced pressure at 30 ° C., and the product obtained was again dissolved in THF and then dropped into an excessive amount of n-hexane to obtain a white precipitate. Was dissolved in THF and then added dropwise to an excess amount of distilled water to obtain a white polymer [NP (OH) (L-Asp. (CH 2 P)
h) 2 )] n was dried under reduced pressure (yield: 85%).
【0022】このように合成したポリホスファゼン誘導
体4.0g(10.7mmol)を溶解したTHF−MeOH
(1:1、vol.%)混合溶液80mlに、KOH1.80
g(32.1mmol)又はNaOH1.28g(32.1mmo
l)を溶解したTHF−MeOH(1:1、vol.%)混
合溶液50mlを徐々に加えた。5時間撹拌後に生成した
沈殿物を濾過し、十分な量のTHF−MeOH混合溶液
とエチルエーテルで洗浄した。沈殿物を2N KOH又は
2N NaOH水溶液40mlに溶解した後、500mlのT
HF−MeOH(1:1、vol.%)混合溶液に滴下して
再結晶し、生成した沈殿物〔NP(OH)(L−Asp
・K2 )〕n 又は〔NP(OH)(Asp・Na2)〕n
を濾過してメタノールとエチルエーテルで洗浄し、乾燥
した(収率:90%)。THF-MeOH in which 4.0 g (10.7 mmol) of the polyphosphazene derivative thus synthesized was dissolved
(1: 1, vol.%) 1.80 KOH was added to 80 ml of the mixed solution.
g (32.1 mmol) or 1.28 g of NaOH (32.1 mmol
50 ml of a mixed solution of l) in THF-MeOH (1: 1, vol.%) was gradually added. The precipitate formed after stirring for 5 hours was filtered and washed with a sufficient amount of a THF-MeOH mixed solution and ethyl ether. After dissolving the precipitate in 40 ml of 2N KOH or 2N aqueous NaOH, 500 ml of T
The mixture was dropped into a mixed solution of HF-MeOH (1: 1, vol.%) And recrystallized, and the resulting precipitate [NP (OH) (L-Asp
.K 2 )] n or [NP (OH) (Asp.Na 2 )] n
Was filtered, washed with methanol and ethyl ether, and dried (yield: 90%).
【0023】一方、白金中間体である(DACH)Pt
I2 2.08g(3.70mmol)とAg2 SO4 1.15
g(3.70mmol)を反応させた後、AgIを濾過、除去
して得た(DACH)PtSO4 水溶液100mlを、上
記で合成した〔NP(OH)(L−Asp・K2 )〕n
1.0g(3.70mmol)の溶解した水溶液30mlに添加
し、光を遮断した状態で1時間撹拌した。反応混合物溶
液に溶けているK2 SO4 を除去するため、反応混合物
を減圧下で30mlに濃縮した。ここにアセトン400ml
を加えて生成した沈殿物をエチルエーテルで洗浄し、減
圧乾燥して最終高分子白金錯化合物を得た。On the other hand, the platinum intermediate (DACH) Pt
2.08 g (3.70 mmol) of I 2 and 1.15 of Ag 2 SO 4
After reacting g (3.70 mmol), AgI was filtered and removed, and 100 ml of a (DACH) PtSO 4 aqueous solution obtained above was synthesized [NP (OH) (L-Asp · K 2 )] n
1.0 g (3.70 mmol) of a dissolved aqueous solution (30 ml) was added, and the mixture was stirred for 1 hour in the absence of light. The reaction mixture was concentrated under reduced pressure to 30 ml to remove the K 2 SO 4 dissolved in the reaction mixture solution. 400 ml of acetone here
Was added, and the resulting precipitate was washed with ethyl ether and dried under reduced pressure to obtain a final polymer platinum complex compound.
【0024】 元素分析値(%): C, 22.3; H, 4.27; N, 9.58; P, 5.
25; Pt, 34.3 理論値(%) : C, 21.6; H, 4.50; N, 10.1; P, 5.
58; Pt, 35.2 水素核磁気共鳴スペクトル(D2O, ppm): 1.2-1.3(4H),
1.6(2H), 2.1(2H), 2.4(2H), 2.7(2H), 3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 516(m), 714(m),
816(m), 1034(m), 1065(m), 1172(m), 1248(m), 1384
(s), 1450(m), 1618(s), 3213(s), 3428(s)Elemental analysis (%): C, 22.3; H, 4.27; N, 9.58; P, 5.
25; Pt, 34.3 Theoretical value (%): C, 21.6; H, 4.50; N, 10.1; P, 5.
58; Pt, 35.2 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.2-1.3 (4H),
1.6 (2H), 2.1 (2H), 2.4 (2H), 2.7 (2H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 516 (m), 714 (m),
816 (m), 1034 (m), 1065 (m), 1172 (m), 1248 (m), 1384
(s), 1450 (m), 1618 (s), 3213 (s), 3428 (s)
【0025】実施例2{NP(OH)〔Asp・Pt(DACH)〕0.5(As
p・K2)0.5・3H2O }n の合成 (DACH)PtI2 1.04g(1.85mmol)、Ag
2 SO4 0.58g(1.85mmol)及び〔NP(OH)
(Asp・K2)〕n 1.0g(3.70mmol)を実施例1
と同様な方法で反応させ高分子白金錯化合物を得た。Example 2 ΔNP (OH) [Asp · Pt (DACH)] 0.5 (As
p · K 2 ) Synthesis of 0.5 · 3H 2 O} n (DACH) PtI 2 1.04 g (1.85 mmol), Ag
0.58 g (1.85 mmol) of 2 SO 4 and [NP (OH)
(Asp · K 2 )] n 1.0 g (3.70 mmol) in Example 1
The reaction was carried out in the same manner as in the above to obtain a polymer platinum complex compound.
【0026】 元素分析値(%): C, 18.5; H, 3.31; N, 5.86; P, 6.
56; Pt, 21.4 理論値(%) : C, 19.1; H, 3.87; N, 6.37; P, 7.
05; Pt, 22.2 水素核磁気共鳴スペクトル(D2O, ppm): 1.2-1.3(4H),
1.6(2H), 2.1(2H), 2.4(2H), 2.7(2H), 3.8(1H) 赤外線スペクトル(KBr cell, cm−1):
518(m), 614(m), 1065(m),
1119(s), 1167(m), 1307
(m), 1393(s), 1591(s), 16
45(m), 2934(m), 3213(s),
3406(s)Elemental analysis (%): C, 18.5; H, 3.31; N, 5.86; P, 6.
56; Pt, 21.4 Theoretical (%): C, 19.1; H, 3.87; N, 6.37; P, 7.
05; Pt, 22.2 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.2-1.3 (4H),
1.6 (2H), 2.1 (2H), 2.4 (2H), 2.7 (2H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ):
518 (m), 614 (m), 1065 (m),
1119 (s), 1167 (m), 1307
(M), 1393 (s), 1591 (s), 16
45 (m), 2934 (m), 3213 (s),
3406 (s)
【0027】実施例3{NP(OH)〔Asp・Pt(DACH)〕
0.2(Asp・K2)0.8・3H2O }n の合成 (DACH)PtI2 0.42g(0.74mmol)、Ag
2 SO4 0.23g(0.74mmol)及び〔NP(OH)
(Asp・K2)〕n 1.0g(3.70mmol)を実施例1
と同様な方法で反応させ高分子白金錯化合物を得た。Example 3 @NP (OH) [Asp.Pt (DACH)]
Synthesis of 0.2 (Asp · K 2 ) 0.8 · 3H 2 O} n (DACH) 0.42 g (0.74 mmol) of PtI 2 , Ag
0.23 g (0.74 mmol) of 2 SO 4 and [NP (OH)
(Asp · K 2 )] n 1.0 g (3.70 mmol) in Example 1
The reaction was carried out in the same manner as in the above to obtain a polymer platinum complex compound.
【0028】 元素分析値(%): C, 15.9; H, 3.14; N, 8.25; P, 7.
38; Pt, 9.77 理論値(%) : C, 16.9; H, 3.76; N, 9.08; P, 8.
36; Pt, 10.54 水素核磁気共鳴スペクトル(D2O, ppm): 1.2-1.3(4H),
1.6(2H), 2.1(2H), 2.4(2H), 2.7(2H), 3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 534(m), 620(m),
979(m), 1060(m), 1124(s), 1205(m), 1307(m), 1404
(s), 1591(s), 2945(m), 3224(s), 3406(s)Elemental analysis (%): C, 15.9; H, 3.14; N, 8.25; P, 7.
38; Pt, 9.77 Theoretical (%): C, 16.9; H, 3.76; N, 9.08; P, 8.
36; Pt, 10.54 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.2-1.3 (4H),
1.6 (2H), 2.1 (2H), 2.4 (2H), 2.7 (2H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 534 (m), 620 (m),
979 (m), 1060 (m), 1124 (s), 1205 (m), 1307 (m), 1404
(s), 1591 (s), 2945 (m), 3224 (s), 3406 (s)
【0029】実施例4{NP(OH)〔Asp・Pt(CPA)2〕0.9(As
p・K2)0.1・2H2O }n の合成 (CPA)2PtI2 2.08g(3.70mmol)、Ag2
SO4 1.15g(3.70mmol)及び〔NP(OH)
(Asp・K2)〕n 1.0g(3.70mmol)を実施例1
と同様な方法で反応させ高分子白金錯化合物を得た。Example 4 ΔNP (OH) [Asp · Pt (CPA) 2 ] 0.9 (As
p · K 2 ) 0.1 · 2H 2 O} n Synthesis of (CPA) 2 PtI 2 2.08 g (3.70 mmol), Ag 2
1.15 g (3.70 mmol) of SO 4 and [NP (OH)
(Asp · K 2 )] n 1.0 g (3.70 mmol) in Example 1
The reaction was carried out in the same manner as in the above to obtain a polymer platinum complex compound.
【0030】 元素分析値(%): C, 21.7; H, 3.82; N, 9.33; P, 5.
18; Pt, 34.7 理論値(%) : C, 21.9; H, 4.23; N, 10.35; P,
6.02; Pt, 34.1 水素核磁気共鳴スペクトル(D2O, ppm): 0.7(8H), 2.5(2
H), 3.7(1H) 赤外線スペクトル(KBr cell, cm-1): 619(m), 827(m),
964(m), 1030(m), 1122(m), 1261(m), 1375(s), 1637
(s), 3103(m), 3188(s), 3404(m)Elemental analysis (%): C, 21.7; H, 3.82; N, 9.33; P, 5.
18; Pt, 34.7 Theoretical (%): C, 21.9; H, 4.23; N, 10.35; P,
6.02; Pt, 34.1 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 0.7 (8H), 2.5 (2
H), 3.7 (1H) Infrared spectrum (KBr cell, cm -1 ): 619 (m), 827 (m),
964 (m), 1030 (m), 1122 (m), 1261 (m), 1375 (s), 1637
(s), 3103 (m), 3188 (s), 3404 (m)
【0031】実施例5{NP(OH)〔Asp・Pt(NH3)2〕・3H2O
}n の合成 (NH3)2 PtI2 1.79g(3.70mmol)、Ag2
SO4 1.15g(3.70mmol)及び〔NP(OH)
(L−Asp・K2)〕n 1.0g(3.70mmol)を実施
例1と同様な方法で反応させ高分子白金錯化合物を得
た。Example 5 ΔNP (OH) [Asp.Pt (NH 3 ) 2 ] .3H 2 O
Synthesis of} n 1.79 g (3.70 mmol) of (NH 3 ) 2 PtI 2 , Ag 2
1.15 g (3.70 mmol) of SO 4 and [NP (OH)
(L-Asp.K 2 )] n (1.0 g, 3.70 mmol) was reacted in the same manner as in Example 1 to obtain a polymer platinum complex compound.
【0032】 元素分析値(%): C, 10.4; H, 2.88; N, 9.54; P, 5.
98; Pt, 40.4 理論値(%) : C, 10.1; H, 3.37; N, 8.84; P, 6.
52; Pt, 41.1 水素核磁気共鳴スペクトル(D2O, ppm): 2.7(2H), 3.9(1
H) 赤外線スペクトル(KBr cell, cm-1): 619(m), 1118(m),
1369(m), 1639(s), 3128(m), 3259(s), 3443(m)Elemental analysis (%): C, 10.4; H, 2.88; N, 9.54; P, 5.
98; Pt, 40.4 Theoretical (%): C, 10.1; H, 3.37; N, 8.84; P, 6.
52; Pt, 41.1 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 2.7 (2H), 3.9 (1
H) Infrared spectrum (KBr cell, cm -1 ): 619 (m), 1118 (m),
1369 (m), 1639 (s), 3128 (m), 3259 (s), 3443 (m)
【0033】実施例6{NP(OH)〔Asp・Pt(en)〕0.85(Asp
・K2)0.15・2H2O }n の合成 (en)PtI2 1.88g(3.70mmol)、Ag2 S
O4 1.15g(3.70mmol)及び〔NP(OH)(L
−Asp・K2)〕n 1.0g(3.70mmol)を実施例1
と同様な方法で反応させ高分子白金錯化合物を得た。Example 6 ΔNP (OH) [Asp · Pt (en)] 0.85 (Asp
· K 2) of 0.15 · 2H 2 O} n Synthesis (en) PtI 2 1.88g (3.70mmol ), Ag 2 S
1.15 g (3.70 mmol) of O 4 and [NP (OH) (L
-Asp.K 2 )] n in Example 1 (1.0 g, 3.70 mmol).
The reaction was carried out in the same manner as in the above to obtain a polymer platinum complex compound.
【0034】 元素分析値(%): C, 15.8; H, 4.54; N, 10.7; P, 6.
11; Pt, 36.4 理論値(%) : C, 15.0; H, 3.55; N, 11.4; P, 6.
78; Pt, 36.3 水素核磁気共鳴スペクトル(D2O, ppm): 2.4-2.6(6H),
3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 570(m), 765(m),
1049(m), 1128(m), 1291(m), 1400(s), 1638(s), 3267
(m), 3450(m)Elemental analysis (%): C, 15.8; H, 4.54; N, 10.7; P, 6.
11; Pt, 36.4 Theoretical value (%): C, 15.0; H, 3.55; N, 11.4; P, 6.
78; Pt, 36.3 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 2.4-2.6 (6H),
3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 570 (m), 765 (m),
1049 (m), 1128 (m), 1291 (m), 1400 (s), 1638 (s), 3267
(m), 3450 (m)
【0035】実施例7{NP(OH)〔Asp・Pt(pn)〕0.85(Asp
・K2)0.15・2H2O }n の合成 (pn)PtI2 1.94g(3.70mmol)、Ag2 S
O4 1.15g(3.70mmol)及び〔NP(OH)(L
−Asp・K2)〕n 1.0g(3.70mmol)を実施例1
と同様な方法で反応させ高分子白金錯化合物を得た。Example 7 ΔNP (OH) [Asp · Pt (pn)] 0.85 (Asp
・ K 2 ) Synthesis of 0.15 · 2H 2 O} n (pn) 1.94 g (3.70 mmol) of PtI 2 , Ag 2 S
1.15 g (3.70 mmol) of O 4 and [NP (OH) (L
-Asp · K 2 )] n in an amount of 1.0 g (3.70 mmol) in Example 1.
The reaction was carried out in the same manner as in the above to obtain a polymer platinum complex compound.
【0036】 元素分析値(%): C, 16.5; H, 4.43; N, 10.7; P, 6.
14; Pt, 35.4 理論値(%) : C, 16.7; H, 3.81; N, 11.0; P, 6.
58; Pt, 35.2 水素核磁気共鳴スペクトル(D2O, ppm): 1.4(2H), 2.4-
2.7(6H), 3.8(1H) 赤外線スペクトル(KBr cell, cm−1):
530(m), 936(m), 1108(m),
1196(m), 1291(m), 1402
(s), 1634(s), 2932(m), 32
24(m), 3428(m)Elemental analysis (%): C, 16.5; H, 4.43; N, 10.7; P, 6.
14; Pt, 35.4 Theoretical value (%): C, 16.7; H, 3.81; N, 11.0; P, 6.
58; Pt, 35.2 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.4 (2H), 2.4-
2.7 (6H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ):
530 (m), 936 (m), 1108 (m),
1196 (m), 1291 (m), 1402
(S), 1634 (s), 2932 (m), 32
24 (m), 3428 (m)
【0037】実施例8{NP(OH)〔Asp・Pt(NH2CH3)
2 〕0.85(Asp・K2)0.15・2H2O }n の合成 (CH3 NH2)2 PtI2 1.89g(3.70mmol)、
Ag2 SO4 1.15g(3.70mmol)及び〔NP(O
H)(L−Asp・K2)〕n 1.0g(3.70mmol)を
実施例1と同様な方法で反応させ高分子白金錯化合物を
得た。Example 8 @NP (OH) [Asp.Pt (NH 2 CH 3 )
2 ] 0.85 (Asp · K 2 ) 0.15 · 2H 2 O} n Synthesis of (CH 3 NH 2 ) 2 PtI 2 1.89 g (3.70 mmol),
1.15 g (3.70 mmol) of Ag 2 SO 4 and [NP (O
H) (L-Asp · K 2 )] n (1.0 g, 3.70 mmol) was reacted in the same manner as in Example 1 to obtain a polymer platinum complex compound.
【0038】 元素分析値(%): C, 15.1; H, 4.58; N, 10.8; P, 6.
36; Pt, 36.5 理論値(%) : C, 14.9; H, 3.91; N, 11.3; P, 6.
76; Pt, 36.2 水素核磁気共鳴スペクトル(D2O, ppm): 2.4-2.7(8H),
3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 582(m), 753(m),
1084(m), 1237(m), 1418(s), 1621(s), 2923(m), 3218
(m), 3421(m)Elemental analysis (%): C, 15.1; H, 4.58; N, 10.8; P, 6.
36; Pt, 36.5 Theoretical (%): C, 14.9; H, 3.91; N, 11.3; P, 6.
76; Pt, 36.2 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 2.4-2.7 (8H),
3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 582 (m), 753 (m),
1084 (m), 1237 (m), 1418 (s), 1621 (s), 2923 (m), 3218
(m), 3421 (m)
【0039】実施例9{NP(OH)〔Asp・Pt(NH2C2H5)2〕
0.8(Asp・K2)0.2・2H2O }n の合成 (NH2 C2 H5)2 PtI2 1.99g(3.70mmo
l)、Ag2 SO4 1.15g(3.70mmol)及び〔N
P(OH)(L−Asp・K2)〕n 1.0g(3.70mm
ol)を実施例1と同様な方法で反応させ高分子白金錯化
合物を得た。Example 9 {NP (OH) [Asp.Pt (NH 2 C 2 H 5 ) 2 ]
Synthesis of 0.8 (Asp · K 2 ) 0.2 · 2H 2 O} n (NH 2 C 2 H 5 ) 2 PtI 2 1.99 g (3.70 mmol)
l), 1.15 g (3.70 mmol) of Ag 2 SO 4 and [N
P (OH) (L-Asp.K 2 )] n 1.0 g (3.70 mm
ol) was reacted in the same manner as in Example 1 to obtain a polymer platinum complex compound.
【0040】 元素分析値(%): C, 18.3; H, 4.32; N, 10.8; P, 6.
20; Pt, 33.6 理論値(%) : C, 18.3; H, 4.40; N, 10.7; P, 6.
56; Pt, 33.1 水素核磁気共鳴スペクトル(D2O, ppm): 1.1(6H), 2.5-
2.8(6H), 3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 603(m), 762(m),
1064(m), 1201(m), 1231(m), 1407(s), 1633(s), 2934
(m), 3214(s), 3402(s)Elemental analysis (%): C, 18.3; H, 4.32; N, 10.8; P, 6.
20; Pt, 33.6 Theoretical value (%): C, 18.3; H, 4.40; N, 10.7; P, 6.
56; Pt, 33.1 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.1 (6H), 2.5-
2.8 (6H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 603 (m), 762 (m),
1064 (m), 1201 (m), 1231 (m), 1407 (s), 1633 (s), 2934
(m), 3214 (s), 3402 (s)
【0041】実施例10{NP(OH)〔Asp・Pt(HDAP)〕
0.8(Asp・K2)0.2・2H2O }n の合成 (HDAP)PtI2 1.99g(3.70mmol)、Ag
2 SO4 1.15g(3.70mmol)及び〔NP(OH)
(L−Asp・K2)〕n 1.0g(3.70mmol)を実施
例1と同様な方法で反応させ高分子白金錯化合物を得
た。Example 10 NP (OH) [Asp.Pt (HDAP)]
Synthesis of 0.8 (Asp · K 2 ) 0.2 · 2H 2 O} n (HDAP) 1.99 g (3.70 mmol) of PtI 2 , Ag
1.15 g (3.70 mmol) of 2 SO 4 and [NP (OH)
(L-Asp.K 2 )] n (1.0 g, 3.70 mmol) was reacted in the same manner as in Example 1 to obtain a polymer platinum complex compound.
【0042】 元素分析値(%): C, 15.9; H, 4.4
2; N, 10.2; P, 6.13; Pt,
33.1 理論値(%) : C, 16.3; H, 3.2
0; N, 10.7; P, 6.56; Pt,
33.1 水素核磁気共鳴スペクトル(D2O, ppm): 2.3-2.5(6H),
3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 532(m), 851(m),
974(m), 1071(m), 1189(m), 1312(m), 1402(s), 1632
(s), 3202(m), 3449(m)Elemental analysis (%): C, 15.9; H, 4.4
2; N, 10.2; P, 6.13; Pt,
33.1 Theoretical value (%): C, 16.3; H, 3.2
0; N, 10.7; P, 6.56; Pt,
33.1 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 2.3-2.5 (6H),
3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 532 (m), 851 (m),
974 (m), 1071 (m), 1189 (m), 1312 (m), 1402 (s), 1632
(s), 3202 (m), 3449 (m)
【0043】実施例11{NP(OH)〔Asp・Pt(DMDAP) 〕
0.8(Asp・K2)0.2・2H2O }n の合成 (DMDAP)PtI2 2.04g(3.70mmol)、A
g2 SO4 1.15g(3.70mmol)及び〔NP(O
H)(L−Asp・K2)〕n 1.0g(3.70mmol)を
実施例1と同様な方法で反応させ高分子白金錯化合物を
得た。Example 11 ΔNP (OH) [Asp · Pt (DMDAP)]
Synthesis of 0.8 (Asp · K 2 ) 0.2 · 2H 2 O} n (DMDAP) 2.04 g (3.70 mmol) of PtI 2 , A
g 2 SO 4 1.15 g (3.70 mmol) and [NP (O
H) (L-Asp · K 2 )] n (1.0 g, 3.70 mmol) was reacted in the same manner as in Example 1 to obtain a polymer platinum complex compound.
【0044】 元素分析値(%): C, 21.4; H, 5.26; N, 9.52; P, 6.
23; Pt, 32.8 理論値(%) : C, 20.0; H, 4.31; N, 10.5; P, 6.
43; Pt, 32.4 水素核磁気共鳴スペクトル(D2O, ppm): 1.4(6H), 2.3-
2.5(6H), 3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 522(m), 700(m),
915(m), 1108(m), 1200(m), 1221(m), 1307(m), 1400
(m), 1632(s), 2945(m), 3224(s), 3442(s)Elemental analysis (%): C, 21.4; H, 5.26; N, 9.52; P, 6.
23; Pt, 32.8 Theoretical (%): C, 20.0; H, 4.31; N, 10.5; P, 6.
43; Pt, 32.4 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.4 (6H), 2.3-
2.5 (6H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 522 (m), 700 (m),
915 (m), 1108 (m), 1200 (m), 1221 (m), 1307 (m), 1400
(m), 1632 (s), 2945 (m), 3224 (s), 3442 (s)
【0045】実施例12{NP(OH)〔Asp・Pt(DAMCB) 〕
0.8(Asp・K2)0.2・2H2O }n の合成 (DAMCB)PtI2 2.08g(3.70mmol)、A
g2 SO4 1.15g(3.70mmol)及び〔NP(O
H)(L−Asp・K2)〕n 1.0g(3.70mmol)を
実施例1と同様な方法で反応させ高分子白金錯化合物を
得た。Example 12 ΔNP (OH) [Asp · Pt (DAMCB)]
Synthesis of 0.8 (Asp · K 2 ) 0.2 · 2H 2 O} n (DAMCB) 2.08 g (3.70 mmol) of PtI 2 , A
g 2 SO 4 1.15 g (3.70 mmol) and [NP (O
H) (L-Asp · K 2 )] n (1.0 g, 3.70 mmol) was reacted in the same manner as in Example 1 to obtain a polymer platinum complex compound.
【0046】 元素分析値(%): C, 22.1; H, 4.51; N, 9.84; P, 5.
87; Pt, 32.1 理論値(%) : C, 21.5; H, 4.23; N, 10.3; P, 6.
31; Pt, 31.8 水素核磁気共鳴スペクトル(D2O, ppm): 0.8-1.1(6H),
2.2-2.4(6H), 3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 530(m), 920(m),
1087(m), 1114(m), 1200(m), 1400(s), 1632(s), 2966
(m), 3224(m), 3442(m)Elemental analysis (%): C, 22.1; H, 4.51; N, 9.84; P, 5.
87; Pt, 32.1 Theoretical value (%): C, 21.5; H, 4.23; N, 10.3; P, 6.
31; Pt, 31.8 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 0.8-1.1 (6H),
2.2-2.4 (6H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 530 (m), 920 (m),
1087 (m), 1114 (m), 1200 (m), 1400 (s), 1632 (s), 2966
(m), 3224 (m), 3442 (m)
【0047】実施例13{NP(OCH3)〔Asp・Pt(DACH)〕
0.8(Asp・K2)0.2・2H2O }n の合成 L−アスパルトイルジベンジルエステル−p−トルエン
スルホン酸塩13.2g(27.2mmol)をTHF400
mlに入れ、0℃で冷却し、トリエチルアミン7.56ml
(54.4mmol)に加えて30分間撹拌した。ここに実
施例1で合成したポリジクロロホスファゼン3.0g を
溶解したTHF溶液150mlを1時間かけて滴下し、室
温で20時間撹拌した。このときに生成した沈殿物(E
t3 N・HCl及びトリエチルアンモニウム−p−トル
エンスルホン酸塩)を濾過した後、濾過液を30℃以下
で30mlに濃縮し、ここにメタノール50mlとトリエチ
ルアミン3.78ml(27.7mmol)を入れ、60〜7
0℃で14時間撹拌した。このときに生成した沈殿物
(Et3 N・HCl)を濾過してから、濾過液の溶媒を
30℃以下で蒸発させ、得た生成物をTHFに溶解し、
過剰量のn−ヘキサンに滴下して、白色の沈殿物を得
た。再びこの沈殿物をTHFに溶解し、過剰量の蒸留水
に滴下して白色の重合体のみを沈殿により得、この工程
を2回繰り返した後、得た重合体〔NP(OCH3)(L
−Asp・(CH2 Ph)2) 〕n を減圧乾燥した。この
ようにして合成したポリホスファゼン誘導体4.0g(1
0.7mmol)を実施例1のように加水分解処理して得た
〔NP(OCH3)(L−Asp・K2)〕n 1.0g(3.
52mmol)と、(DACH)PtI2 1.98g(3.5
2mmol)及びAgSO4 1.10g(3.52mmol)を実
施例1と同様な方法で反応させ高分子白金錯化合物を得
た。Example 13 ΔNP (OCH 3 ) [Asp · Pt (DACH)]
Synthesis of 0.8 (Asp · K 2 ) 0.2 · 2H 2 O} n 13.2 g (27.2 mmol) of L-aspartyl dibenzyl ester-p-toluenesulfonate was added to THF 400
and cooled at 0 ° C. to 7.56 ml of triethylamine.
(54.4 mmol) and stirred for 30 minutes. 150 ml of a THF solution in which 3.0 g of the polydichlorophosphazene synthesized in Example 1 was dissolved was added dropwise over 1 hour, and the mixture was stirred at room temperature for 20 hours. The precipitate (E
After filtration of t 3 N · HCl and triethylammonium-p-toluenesulfonate), the filtrate was concentrated to 30 ml at 30 ° C. or lower, and 50 ml of methanol and 3.78 ml (27.7 mmol) of triethylamine were added thereto. 60-7
Stirred at 0 ° C. for 14 hours. The precipitate (Et 3 N · HCl) generated at this time was filtered, and then the solvent of the filtrate was evaporated at 30 ° C. or lower, and the obtained product was dissolved in THF.
A white precipitate was obtained by dropwise addition to excess n-hexane. This precipitate was dissolved again in THF and dropped into an excessive amount of distilled water to obtain only a white polymer by precipitation. After repeating this step twice, the obtained polymer [NP (OCH 3 ) (L
The -Asp · (CH 2 Ph) 2 ) ] n and dried under reduced pressure. 4.0 g of the polyphosphazene derivative synthesized in this manner (1
[NP (OCH 3 ) (L-Asp · K 2 )] n (1.0 g, 0.7 mmol).
52 mmol) and 1.98 g of (DACH) PtI 2 (3.5
2 mmol) and 1.10 g (3.52 mmol) of AgSO 4 were reacted in the same manner as in Example 1 to obtain a polymer platinum complex compound.
【0048】 元素分析値(%): C, 23.4; H, 4.45; N, 9.67; P, 5.
88; Pt, 31.8 理論値(%) : C, 23.3; H, 4.51; N, 9.98; P, 6.
13; Pt, 30.9 水素核磁気共鳴スペクトル(D2O, ppm): 1.2-1.3(4H),
1.6(2H), 2.2(2H), 2.5(2H), 2.7(2H), 3.4(3H), 3.8(1
H) 赤外線スペクトル(KBr cell, cm-1): 516(m), 613(m),
1110(m), 1034(m), 1172(m), 1253(m), 1398(s), 1594
(s), 2940(m), 3218(s), 3246(m)Elemental analysis (%): C, 23.4; H, 4.45; N, 9.67; P, 5.
88; Pt, 31.8 Theoretical (%): C, 23.3; H, 4.51; N, 9.98; P, 6.
13; Pt, 30.9 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.2-1.3 (4H),
1.6 (2H), 2.2 (2H), 2.5 (2H), 2.7 (2H), 3.4 (3H), 3.8 (1
H) Infrared spectrum (KBr cell, cm -1 ): 516 (m), 613 (m),
1110 (m), 1034 (m), 1172 (m), 1253 (m), 1398 (s), 1594
(s), 2940 (m), 3218 (s), 3246 (m)
【0049】実施例14{NP(OCH3)〔Asp・Pt(NH3)2〕
0.85(Asp・K2)0.15・2H2O }n の合成 (NH3)2 PtI2 1.78g(3.52mmol)、Ag2
SO4 1.10g(3.52mmol)及び〔NP(OCH3)
(Asp・K2)〕n 1.0g(3.52mmol)を実施例1
3と同様な方法で反応させ高分子白金錯化合物を得た。Example 14 ΔNP (OCH 3 ) [Asp.Pt (NH 3 ) 2 ]
Synthesis of 0.85 (Asp · K 2 ) 0.15 · 2H 2 O} n (NH 3 ) 2 PtI 2 1.78 g (3.52 mmol), Ag 2
1.10 g (3.52 mmol) of SO 4 and [NP (OCH 3 )
(Asp · K 2 )] n 1.0 g (3.52 mmol) in Example 1
Reaction was carried out in the same manner as in Example 3 to obtain a polymer platinum complex compound.
【0050】 元素分析値(%): C, 13.1; H, 4.33; N, 11.0; P, 7.
42; Pt, 37.1 理論値(%) : C, 13.5; H, 3.64; N, 11.6; P, 6.
94; Pt, 37.2 水素核磁気共鳴スペクトル(D2O, ppm): 2.5(2H), 3.3(3
H), 3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 520(m), 714(m),
1038(m), 1174(m), 1205(m), 1377(s), 1624(s), 2927
(m), 3267(s), 3442(m)Elemental analysis (%): C, 13.1; H, 4.33; N, 11.0; P, 7.
42; Pt, 37.1 Theoretical value (%): C, 13.5; H, 3.64; N, 11.6; P, 6.
94; Pt, 37.2 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 2.5 (2H), 3.3 (3
H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 520 (m), 714 (m),
1038 (m), 1174 (m), 1205 (m), 1377 (s), 1624 (s), 2927
(m), 3267 (s), 3442 (m)
【0051】実施例15{NP(OC2H5) 〔Asp・Pt(DACH)〕
0.8(Asp・K2)0.2・2H2O }n の合成 ポリジクロロホスファゼン3.0g 、L−アスパルトイ
ルジベンジルエステル−p−トルエンスルホン酸塩1
3.2g(27.2mmol)及びエタノール(50ml)を反
応させて得た〔NP(OC2 H5)(L−Asp・K2)〕
n 1.0g(3.34mmol)と、(DACH)PtI2
1.88g(3.34mmol)及びAg2 SO41.04g
(3.34mmol)を実施例13と同様な方法で反応させ
高分子白金錯化合物を得た。Example 15 ΔNP (OC 2 H 5 ) [Asp · Pt (DACH)]
0.8 (Asp · K 2 ) 0.2 · 2H 2 O} n Synthesis 3.0 g of polydichlorophosphazene, L-aspartoyldibenzyl ester-p-toluenesulfonate 1
3.2 g (27.2 mmol) and ethanol (50ml) was prepared by reacting [NP (OC 2 H 5) ( L-Asp · K 2) ]
n 1.0 g (3.34 mmol) and (DACH) PtI 2
1.88 g (3.34 mmol) and 1.04 g of Ag 2 SO 4
(3.34 mmol) was reacted in the same manner as in Example 13 to obtain a polymer platinum complex compound.
【0052】 元素分析値(%): C, 28.7; H, 5.10; N, 9.01; P, 5.
58; Pt, 29.1 理論値(%) : C, 28.6; H, 4.69; N, 9.69; P, 5.
95; Pt, 30.0 水素核磁気共鳴スペクトル(D2O, ppm): 1.1-1.3(4H),
1.4-1.6(6H), 2.2(2H),2.4(2H), 2.8(2H), 3.4(2H), 3.
8(1H) 赤外線スペクトル(KBr cell, cm-1): 516(m), 614(m),
963(m), 1032(m), 1122(m), 1173(m), 1248(m), 1302
(m), 1390(s), 1624(s), 2923(m), 3212(s), 3426(s)Elemental analysis (%): C, 28.7; H, 5.10; N, 9.01; P, 5.
58; Pt, 29.1 Theoretical (%): C, 28.6; H, 4.69; N, 9.69; P, 5.
95; Pt, 30.0 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.1-1.3 (4H),
1.4-1.6 (6H), 2.2 (2H), 2.4 (2H), 2.8 (2H), 3.4 (2H), 3.
8 (1H) Infrared spectrum (KBr cell, cm -1 ): 516 (m), 614 (m),
963 (m), 1032 (m), 1122 (m), 1173 (m), 1248 (m), 1302
(m), 1390 (s), 1624 (s), 2923 (m), 3212 (s), 3426 (s)
【0053】実施例16{NP(OC2H5) 〔Asp・Pt(NH3)2〕
0.85(Asp・K2)0.15・2H2O }n の合成 (NH3)2 PtI2 1.61g(3.34mmol)、Ag2
SO4 1.04g(3.34mmol)及び〔NP(OC2 H
5)(Asp・K2)〕n 1.0g(3.34mmol)を実施例
13と同様な方法で反応させ高分子白金錯化合物を得
た。Example 16 ΔNP (OC 2 H 5 ) [Asp · Pt (NH 3 ) 2 ]
Synthesis of 0.85 (Asp · K 2 ) 0.15 · 2H 2 O} n 1.61 g (3.34 mmol) of (NH 3 ) 2 PtI 2 , Ag 2
1.04 g (3.34 mmol) of SO 4 and [NP (OC 2 H
5 ) (Asp · K 2 )] n (1.0 g, 3.34 mmol) was reacted in the same manner as in Example 13 to obtain a polymer platinum complex compound.
【0054】 元素分析値(%): C, 19.8; H, 4.4
6; N, 10.9; P, 6.01; Pt,
35.8 理論値(%) : C, 20.1; H, 3.9
6; N, 11.2; P, 6.72; Pt,
36.0 水素核磁気共鳴スペクトル(D2O, ppm): 1.3(3H), 2.6(2
H), 3.3(2H), 3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 601(m), 889(m),
1043(m), 1218(m), 1382(s), 1630(s), 2936(m), 3213
(s), 3426(s)Elemental analysis value (%): C, 19.8; H, 4.4
6; N, 10.9; P, 6.01; Pt,
35.8 Theoretical value (%): C, 20.1; H, 3.9
6; N, 11.2; P, 6.72; Pt,
36.0 hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.3 (3H), 2.6 (2
H), 3.3 (2H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 601 (m), 889 (m),
1043 (m), 1218 (m), 1382 (s), 1630 (s), 2936 (m), 3213
(s), 3426 (s)
【0055】実施例17{NP(OC2H4OCH3) 〔Asp・Pt(DAC
H)〕0.8(Asp・K2)0.2・2H2O }n の合成 ポリジクロロホスファゼン3.0g 、L−アスパルトイ
ルジベンジルエステル−p−トルエンスルホン酸塩1
3.2g(27.2mmol)及びCH3 OCH2 CH2 ON
a2.70g(27.2mmol)を反応させて得た〔NP
(OCH2 CH2 OCH3)(L−Asp・K2)〕n 1.
0g(3.04mmol)と、(DACH)PtI2 1.71
g(3.04mmol)及びAg2 SO4 0.95g(3.04
mmol)を実施例13と同様な方法で反応させ高分子白金
錯化合物を得た。Example 17 ΔNP (OC 2 H 4 OCH 3 ) [Asp · Pt (DAC
H)] 0.8 (Asp · K 2 ) 0.2 · 2H 2 O} n Synthesis of 3.0 g of polydichlorophosphazene, L-aspartoyldibenzyl ester-p-toluenesulfonate 1
3.2 g (27.2 mmol) and CH 3 OCH 2 CH 2 ON
a. obtained by reacting 2.70 g (27.2 mmol) of a
(OCH 2 CH 2 OCH 3 ) (L-Asp · K 2 )] n 1.
0 g (3.04 mmol) and (DACH) PtI 2 1.71
g (3.04 mmol) and 0.95 g of Ag 2 SO 4 (3.04
mmol) was reacted in the same manner as in Example 13 to obtain a polymer platinum complex compound.
【0056】 元素分析値(%): C, 25.7; H, 5.38; N, 8.76; P, 5.
10; Pt, 28.9 理論値(%) : C, 25.8; H, 4.81; N, 9.18; P, 5.
64; Pt, 28.4 水素核磁気共鳴スペクトル(D2O, ppm): 1.2-1.4(6H),
1.6(2H), 2.1(2H), 2.4(2H), 2.7(2H), 3.2-3.4(5H),
3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 516(m), 840(m),
969(m), 1044(m), 1124(m), 1162(m), 1205(m), 1253
(m), 1398(s), 1624(m), 2940(m), 3234(s), 3440(s)Elemental analysis (%): C, 25.7; H, 5.38; N, 8.76; P, 5.
10; Pt, 28.9 Theoretical (%): C, 25.8; H, 4.81; N, 9.18; P, 5.
64; Pt, 28.4 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.2-1.4 (6H),
1.6 (2H), 2.1 (2H), 2.4 (2H), 2.7 (2H), 3.2-3.4 (5H),
3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 516 (m), 840 (m),
969 (m), 1044 (m), 1124 (m), 1162 (m), 1205 (m), 1253
(m), 1398 (s), 1624 (m), 2940 (m), 3234 (s), 3440 (s)
【0057】実施例18{NP(NHCH3) 〔Asp・Pt(DACH)〕
0.8(Asp・K2)0.2・2H2O }n の合成 L−アスパルトイルジベンジルエステル−p−トルエン
スルホン酸塩13.2g(27.2mmol)をTHF400
mlに入れ、0℃で冷却し、トリエチルアミン7.56ml
(54.4mmol)に加えて30分間撹拌した。ここに実
施例1で合成したポリジクロロホスファゼン3.0g の
溶解しているTHF溶液150mlを1時間かけて滴下し
てから室温で20時間撹拌した。このときに生成した沈
殿物(Et3 N・HCl及びトリエチルアンモニウム−
p−トルエンスルホン酸塩)を濾過した後、濾過液を0
℃で冷却し、(ドライアイス−アセトン混合冷媒で液化
した)メチルアミン54.4mmolを加えた後、10時間
撹拌した。反応物の溶媒を取り除き、得られた生成物を
50mlのメタノールに溶解した後、透析膜(分子量カッ
トオフ:1,000)を用いて48時間透析し、溶液を
30mlに濃縮してから、過剰量のアセトンに滴下して白
色の重合体のみを沈殿物として得た。前記で合成したポ
リホスファゼン誘導体4.0g(9.89mmol)を実施例
1のように加水分解処理して得た〔NP(NHCH3)
(L−Asp・K2)〕n 1.0g(3.70mmol)と、
(DACH)PtI2 2.08g(3.70mmol)及びA
g2 SO41.15g(3.70mmol)を実施例1と同様
な方法で反応させ高分子白金錯化合物を得た。Example 18 {NP (NHCH 3 ) [Asp · Pt (DACH)]
Synthesis of 0.8 (Asp · K 2 ) 0.2 · 2H 2 O} n 13.2 g (27.2 mmol) of L-aspartyl dibenzyl ester-p-toluenesulfonate was added to THF 400
and cooled at 0 ° C. to 7.56 ml of triethylamine.
(54.4 mmol) and stirred for 30 minutes. A solution of 3.0 g of polydichlorophosphazene synthesized in Example 1 in 150 ml of THF was added dropwise over 1 hour, and the mixture was stirred at room temperature for 20 hours. Precipitate formed at this time (Et 3 N · HCl and triethylammonium -
After filtration of (p-toluenesulfonate), the filtrate was concentrated to 0%.
After cooling at 0 ° C. and adding 54.4 mmol of methylamine (liquefied with a dry ice-acetone mixed refrigerant), the mixture was stirred for 10 hours. After removing the solvent of the reaction product and dissolving the obtained product in 50 ml of methanol, the solution was dialyzed for 48 hours using a dialysis membrane (molecular weight cutoff: 1,000), and the solution was concentrated to 30 ml. The mixture was added dropwise to a quantity of acetone to obtain only a white polymer as a precipitate. 4.0 g (9.89 mmol) of the polyphosphazene derivative synthesized above was hydrolyzed as in Example 1 to obtain [NP (NHCH 3 )].
(L-Asp · K 2 )] n (1.0 g, 3.70 mmol);
(DACH) 2.08 g (3.70 mmol) of PtI 2 and A
1.15 g (3.70 mmol) of g 2 SO 4 was reacted in the same manner as in Example 1 to obtain a polymer platinum complex compound.
【0058】 元素分析値(%): C, 24.8; H, 4.62; N, 12.4; P, 5.
92; Pt, 30.8 理論値(%) : C, 24.3; H, 4.64; N, 12.8; P, 6.
14; Pt, 31.0 水素核磁気共鳴スペクトル(D2O, ppm): 1.2-1.4(4H),
1.6(2H), 2.1(2H), 2.4-2.6(7H), 3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 518(m), 614(m),
716(m), 904(m), 1060(m), 1114(m), 1248(m), 1307
(m), 1162(m), 1387(s), 1586(s), 1645(s), 2923(m),
3245(s), 3385(s)Elemental analysis (%): C, 24.8; H, 4.62; N, 12.4; P, 5.
92; Pt, 30.8 Theoretical value (%): C, 24.3; H, 4.64; N, 12.8; P, 6.
14; Pt, 31.0 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.2-1.4 (4H),
1.6 (2H), 2.1 (2H), 2.4-2.6 (7H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 518 (m), 614 (m),
716 (m), 904 (m), 1060 (m), 1114 (m), 1248 (m), 1307
(m), 1162 (m), 1387 (s), 1586 (s), 1645 (s), 2923 (m),
3245 (s), 3385 (s)
【0059】実施例19{NP(NHCH3) 〔Asp・Pt(NH3)2〕
0.85(Asp・K2)0.15・2H2O }n の合成 (NH3)2 PtI2 1.79g(3.70mmol)、Ag2
SO4 1.15g(3.70mmol)及び〔NP(NHCH
3)(L−Asp・K2)〕n 1.0g(3.70mmol)を実
施例18と同様な方法で反応させ高分子白金錯化合物を
得た。Example 19 ΔNP (NHCH 3 ) [Asp · Pt (NH 3 ) 2 ]
Synthesis of 0.85 (Asp · K 2 ) 0.15 · 2H 2 O} n (NH 3 ) 2 PtI 2 1.79 g (3.70 mmol), Ag 2
1.15 g (3.70 mmol) of SO 4 and [NP (NHCH
3 ) (L-Asp · K 2 )] n (1.0 g, 3.70 mmol) was reacted in the same manner as in Example 18 to obtain a polymer platinum complex compound.
【0060】 元素分析値(%): C, 13.3; H, 4.28; N, 14.7; P, 6.
89; Pt, 37.4 理論値(%) : C, 13.5; H, 3.87; N, 14.8; P, 6.
96; Pt, 37.3 水素核磁気共鳴スペクトル(D2O, ppm): 2.5(3H), 2.7(2
H), 3.9(1H) 赤外線スペクトル(KBr cell, cm−1):
518(m), 963(m), 1114(m),
1162(m), 1231(m), 1253
(m), 1302(m), 1401(s), 16
39(s), 2945(m), 3245(s),
3421(s)Elemental analysis (%): C, 13.3; H, 4.28; N, 14.7; P, 6.
89; Pt, 37.4 Theoretical value (%): C, 13.5; H, 3.87; N, 14.8; P, 6.
96; Pt, 37.3 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 2.5 (3H), 2.7 (2
H), 3.9 (1H) Infrared spectrum (KBr cell, cm -1 ):
518 (m), 963 (m), 1114 (m),
1162 (m), 1231 (m), 1253
(M), 1302 (m), 1401 (s), 16
39 (s), 2945 (m), 3245 (s),
3421 (s)
【0061】実施例20{NP(N(CH3)2)
〔Asp・Pt(DACH)〕0.8(Asp・K2)0.2・2H2O }n の合成 ポリジクロロホスファゼン3.0g 、L−アスパルトイ
ルジベンジルエステル−p−トルエンスルホン酸塩1
3.2g(27.2mmol)及びジメチルアミンヒドロクロ
リド2.22g(27.2mmol)を反応させて得た〔NP
(N(CH3)2)(L−Asp・K2)〕n 1.0g(3.3
6mmol)と、(DACH)PtI2 1.89g(3.36
mmol)及びAg2 SO4 1.05g(3.36mmol)を実
施例18と同様な方法で反応させ高分子白金錯化合物を
得た。Example 20 @NP (N (CH 3 ) 2 )
[Asp · Pt (DACH)] 0.8 (Asp · K 2 ) 0.2 · 2H 2 O} n Synthesis of polydichlorophosphazene 3.0 g, L-aspartoyldibenzyl ester-p-toluenesulfonate 1
It was obtained by reacting 3.2 g (27.2 mmol) with 2.22 g (27.2 mmol) of dimethylamine hydrochloride [NP
(N (CH 3 ) 2 ) (L-Asp · K 2 )] n 1.0 g (3.3
6 mmol) and 1.89 g (3.36) of (DACH) PtI 2.
mmol) and 1.05 g (3.36 mmol) of Ag 2 SO 4 were reacted in the same manner as in Example 18 to obtain a polymer platinum complex compound.
【0062】 元素分析値(%): C, 23.6; H, 4.98; N, 11.9; P, 5.
83; Pt, 30.7 理論値(%) : C, 23.6; H, 4.90; N, 12.4; P, 5.
98; Pt, 30.1 水素核磁気共鳴スペクトル(D2O, ppm): 1.1-1.3(4H),
1.5(2H), 2.1(2H), 2.3-2.5(8H), 3.9(1H) 赤外線スペクトル(KBr cell, cm-1): 502(m), 625(m),
985(m), 1065(m), 1151(m), 1237(m), 1291(m), 1392
(s), 1632(s), 2923(m), 3191(s), 3442(s)Elemental analysis (%): C, 23.6; H, 4.98; N, 11.9; P, 5.
83; Pt, 30.7 Theoretical value (%): C, 23.6; H, 4.90; N, 12.4; P, 5.
98; Pt, 30.1 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.1-1.3 (4H),
1.5 (2H), 2.1 (2H), 2.3-2.5 (8H), 3.9 (1H) Infrared spectrum (KBr cell, cm -1 ): 502 (m), 625 (m),
985 (m), 1065 (m), 1151 (m), 1237 (m), 1291 (m), 1392
(s), 1632 (s), 2923 (m), 3191 (s), 3442 (s)
【0063】実施例21{NP(OH)〔Glt・Pt(DACH)〕
0.9(Glt・K2)0.1・2H2O }n の合成 ポリジクロロホスファゼン3.0g 、L−グルタモイル
ジベンジルエステル−p−トルエンスルホン酸塩13.
6g(27.2mmol)、トリエチルアミン7.57ml(5
4.4mmol)及びH2 O 0.49ml(27.2mmol)
を反応させて得た〔NP(OH)(L−Glt・K2)〕
n 1.0g(3.52mmol)と、(DACH)PtI2
1.98g(3.52mmol)及びAg2 SO4 1.10g
(3.52mmol)を実施例1と同様な方法で反応させ高
分子白金錯化合物を含む反応混合物を得、これを半透膜
(分子量カットオフ:1,000)を用いて15時間透
析して副産物であるK2 SO4 を取り除いた。精製され
たこの溶液を減圧下に凍結乾燥して、高分子白金錯化合
物を得た。Example 21 ΔNP (OH) [Glt · Pt (DACH)]
Synthesis of 0.9 (Glt · K 2 ) 0.1 · 2H 2 O} n 3.0 g of polydichlorophosphazene, L-glutamoyl dibenzyl ester-p-toluenesulfonate 13.
6 g (27.2 mmol), 7.57 ml of triethylamine (5
4.4 mmol) and H 2 O 0.49ml (27.2mmol)
[NP (OH) (L-Glt · K 2 )]
n (1.0 g, 3.52 mmol) and (DACH) PtI 2
1.98 g (3.52 mmol) and 1.10 g of Ag 2 SO 4
(3.52 mmol) was reacted in the same manner as in Example 1 to obtain a reaction mixture containing a high-molecular platinum complex, which was dialyzed for 15 hours using a semipermeable membrane (molecular weight cutoff: 1,000). By-product K 2 SO 4 was removed. This purified solution was freeze-dried under reduced pressure to obtain a polymer platinum complex compound.
【0064】 元素分析値(%): C, 23.6; H, 4.21; N, 9.59; P, 6.
08; Pt, 34.0 理論値(%) : C, 23.6; H, 4.5
0; N, 10.1; P, 5.86; Pt,
33.2 水素核磁気共鳴スペクトル(D2O, ppm):
1.1−1.3(4H), 1.5(2H), 2.0
(4H), 2.3(4H), 3.7(1H) 赤外線スペクトル(KBr cell, cm-1): 518(m), 615(m),
829(m), 1033(m), 1064(m), 1170(m), 1345(m), 1400
(s), 1447(m), 1634(s), 2937(m), 3234(s), 3422(s)Elemental analysis (%): C, 23.6; H, 4.21; N, 9.59; P, 6.
08; Pt, 34.0 theoretical (%): C, 23.6; H, 4.5
0; N, 10.1; P, 5.86; Pt,
33.2 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm):
1.1-1.3 (4H), 1.5 (2H), 2.0
(4H), 2.3 (4H), 3.7 (1H) Infrared spectrum (KBr cell, cm -1 ): 518 (m), 615 (m),
829 (m), 1033 (m), 1064 (m), 1170 (m), 1345 (m), 1400
(s), 1447 (m), 1634 (s), 2937 (m), 3234 (s), 3422 (s)
【0065】実施例22{NP(OH)〔Glt・Pt(CPA)2〕
0.9(Glt・K2)0.1・2H2O }n の合成 (CPA)2PtI2 1.98g(3.52mmol)、Ag2
SO4 1.10g(3.52mmol)及び〔NP(OH)
(Glt・K2)〕n 1.0g(3.52mmol)を実施例2
1と同様な方法で反応させ高分子白金錯化合物を得た。Example 22 ΔNP (OH) [Glt · Pt (CPA) 2 ]
Synthesis of 0.9 (Glt · K 2 ) 0.1 · 2H 2 O} n (CPA) 2 PtI 2 1.98 g (3.52 mmol), Ag 2
1.10 g (3.52 mmol) of SO 4 and [NP (OH)
(Glt · K 2 )] n Example 1 (1.0 g, 3.52 mmol)
Reaction was carried out in the same manner as in Example 1 to obtain a polymer platinum complex compound.
【0066】 元素分析値(%): C, 24.1; H, 3.98; N, 9.10; P, 4.
97; Pt, 34.0 理論値(%) : C, 23.6; H, 4.50; N, 10.1; P, 5.
86; Pt, 33.2 水素核磁気共鳴スペクトル(D2O, ppm): 0.7(8H), 2.1-
2.4(6H), 3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 1124(m), 1388
(s), 1631(s), 3086(s),3184(s)Elemental analysis (%): C, 24.1; H, 3.98; N, 9.10; P, 4.
97; Pt, 34.0 Theoretical value (%): C, 23.6; H, 4.50; N, 10.1; P, 5.
86; Pt, 33.2 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 0.7 (8H), 2.1-
2.4 (6H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 1124 (m), 1388
(s), 1631 (s), 3086 (s), 3184 (s)
【0067】実施例23{NP(OH)〔Glt・Pt(NH3)2〕・3H2
O }n の合成 (NH3)2 PtI2 1.70g(3.52mmol)、Ag2
SO4 1.10g(3.52mmol)及び〔NP(OH)
(Glt・K2)〕n 1.0g(3.52mmol)を実施例2
1と同様な方法で反応させ高分子白金錯化合物を得た。Example 23 {NP (OH) [Glt · Pt (NH 3 ) 2 ] · 3H 2
Synthesis of O} n 1.70 g (3.52 mmol) of (NH 3 ) 2 PtI 2 , Ag 2
1.10 g (3.52 mmol) of SO 4 and [NP (OH)
(Glt · K 2 )] n Example 1 (1.0 g, 3.52 mmol)
Reaction was carried out in the same manner as in Example 1 to obtain a polymer platinum complex compound.
【0068】 元素分析値(%): C, 12.0; H, 3.21; N, 10.1; P, 5.
83; Pt, 38.4 理論値(%) : C, 12.3; H, 3.88; N, 11.5; P, 6.
33; Pt, 39.9 水素核磁気共鳴スペクトル(D2O, ppm): 2.2(2H), 2.5(2
H), 3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 526(m), 617(m),
857(m), 1111(m), 1344(m), 1386(s), 1628(s), 2960
(m), 3092(s), 3250(s), 3460(s)Elemental analysis (%): C, 12.0; H, 3.21; N, 10.1; P, 5.
83; Pt, 38.4 Theoretical value (%): C, 12.3; H, 3.88; N, 11.5; P, 6.
33; Pt, 39.9 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 2.2 (2H), 2.5 (2
H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 526 (m), 617 (m),
857 (m), 1111 (m), 1344 (m), 1386 (s), 1628 (s), 2960
(m), 3092 (s), 3250 (s), 3460 (s)
【0069】実施例24{NP(OH)〔Glt・Pt(THPDMA)〕
0.8(Glt・K2)0.2 ・2H2O}n の合成 (THPDMA)PtI2 2.09g(3.52mmol)、
Ag2 SO4 1.10g(3.52mmol)及び〔NP(O
H)(Glt・K2)〕n 1.0g(3.52mmol)を実施
例21と同様な方法で反応させ高分子白金錯化合物を得
た。Example 24 ΔNP (OH) [Glt · Pt (THPDMA)]
Synthesis of 0.8 (Glt · K 2 ) 0.2 · 2H 2 O} n (THPDMA) 2.09 g (3.52 mmol) of PtI 2 ,
1.10 g (3.52 mmol) of Ag 2 SO 4 and [NP (O
H) (Glt · K 2 )] n (1.0 g, 3.52 mmol) was reacted in the same manner as in Example 21 to obtain a polymer platinum complex compound.
【0070】 元素分析値(%): C, 23.8; H, 4.33; N, 10.7; P, 5.
45; Pt, 31.5 理論値(%) : C, 24.1; H, 4.53; N, 9.53; P, 5.
85; Pt, 29.5 水素核磁気共鳴スペクトル(D2O, ppm): 1.5(4H), 2.4-
2.6(8H), 3.7(5H) 赤外線スペクトル(KBr cell, cm-1): 518(m), 620(m),
1116(m), 1167(m), 1384(s), 1638(s), 2945(m), 3234
(s), 3446(s)Elemental analysis (%): C, 23.8; H, 4.33; N, 10.7; P, 5.
45; Pt, 31.5 Theory (%): C, 24.1; H, 4.53; N, 9.53; P, 5.
85; Pt, 29.5 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.5 (4H), 2.4-
2.6 (8H), 3.7 (5H) Infrared spectrum (KBr cell, cm -1 ): 518 (m), 620 (m),
1116 (m), 1167 (m), 1384 (s), 1638 (s), 2945 (m), 3234
(s), 3446 (s)
【0071】実施例25{NP(OH)〔Glt・Pt(BAMPDO)〕
0.8(Glt・K2)0.2 ・2H2O}n の合成 (BAMPDO)PtI2 2.05g(3.52mmol)、
Ag2 SO4 1.10g(3.52mmol)及び〔NP(O
H)(Glt・K2)〕n 1.0g(3.52mmol)を実施
例21と同様な方法で反応させ高分子白金錯化合物を得
た。Example 25 ΔNP (OH) [Glt · Pt (BAMPDO)]
Synthesis of 0.8 (Glt · K 2 ) 0.2 · 2H 2 O} n (BAMPDO) PtI 2 2.05 g (3.52 mmol),
1.10 g (3.52 mmol) of Ag 2 SO 4 and [NP (O
H) (Glt · K 2 )] n (1.0 g, 3.52 mmol) was reacted in the same manner as in Example 21 to obtain a polymer platinum complex compound.
【0072】 元素分析値(%): C, 22.4; H, 5.62; N, 11.6; P, 6.
12; Pt, 34.2 理論値(%) : C, 22.3; H, 4.61; N, 10.4; P, 6.
38; Pt, 32.2 水素核磁気共鳴スペクトル(D2O, ppm): 2.0-2.6(12H),
3.6(1H) 赤外線スペクトル(KBr cell, cm-1): 526(m), 1044(m),
1228(m), 1275(m), 1384(s), 1457(m), 1618(s), 2925
(m), 3202(s), 3404(s)Elemental analysis (%): C, 22.4; H, 5.62; N, 11.6; P, 6.
12; Pt, 34.2 Theoretical (%): C, 22.3; H, 4.61; N, 10.4; P, 6.
38; Pt, 32.2 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 2.0-2.6 (12H),
3.6 (1H) Infrared spectrum (KBr cell, cm -1 ): 526 (m), 1044 (m),
1228 (m), 1275 (m), 1384 (s), 1457 (m), 1618 (s), 2925
(m), 3202 (s), 3404 (s)
【0073】実施例26{NP(OCH3)〔Glt・Pt(DACH)〕
0.8(Glt・K2)0.2 ・2H2O}n の合成 ポリジクロロホスファゼン3.0g 、L−グルタモイル
ジベンジルエステル−p−トルエンスルホン酸塩13.
6g(27.2mmol)及びメタノール50mlを反応させて
得た〔NP(OCH3)(L−Glt・K2)〕n 1.0g
(3.35mmol)と、(DACH)PtI2 1.89g
(3.35mmol)及びAg2 SO4 1.04g(3.35m
mol)を実施例13と同様な方法で反応させ高分子白金
錯化合物を得た。Example 26 ΔNP (OCH 3 ) [Glt · Pt (DACH)]
0.8 (Glt · K 2 ) Synthesis of 0.2 · 2H 2 O} n 3.0 g of polydichlorophosphazene, L-glutamoyl dibenzyl ester-p-toluenesulfonate 13.
1.0 g of [NP (OCH 3 ) (L-Glt · K 2 )] n obtained by reacting 6 g (27.2 mmol) and 50 ml of methanol.
(3.35 mmol) and 1.89 g of (DACH) PtI 2
(3.35 mmol) and 1.04 g of Ag 2 SO 4 (3.35 m
mol) was reacted in the same manner as in Example 13 to obtain a polymer platinum complex compound.
【0074】 元素分析値(%): C, 25.0; H, 4.66; N, 9.26; P, 5.
90; Pt, 29.4 理論値(%) : C, 25.0; H, 4.70; N, 9.71; P, 5.
97; Pt, 30.1 水素核磁気共鳴スペクトル(D2O, ppm): 1.1-1.3(4H),
1.5(2H), 2.1(4H), 2.4(4H), 3.3(3H), 3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 514(m), 609(m),
813(m), 1052(m), 1170(m), 1213(m), 1240(m), 1387
(s), 1618(s), 2940(m), 3254(s), 3420(s)Elemental analysis (%): C, 25.0; H, 4.66; N, 9.26; P, 5.
90; Pt, 29.4 Theoretical (%): C, 25.0; H, 4.70; N, 9.71; P, 5.
97; Pt, 30.1 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.1-1.3 (4H),
1.5 (2H), 2.1 (4H), 2.4 (4H), 3.3 (3H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 514 (m), 609 (m),
813 (m), 1052 (m), 1170 (m), 1213 (m), 1240 (m), 1387
(s), 1618 (s), 2940 (m), 3254 (s), 3420 (s)
【0075】実施例27{NP(OCH3)〔Glt・Pt(NH3)2〕
0.85(Glt・K2)0.15 ・2H2O}n の合成 (NH3)2 PtI2 1.62g(3.35mmol)、Ag2
SO4 1.04g(3.69mmol)及び〔NP(OCH3)
(Glt・K2)〕n 1.0g(3.35mmol)を実施例2
6と同様な方法で反応させ高分子白金錯化合物を得た。Example 27 {NP (OCH 3 ) [Glt · Pt (NH 3 ) 2 ]
Synthesis of 0.85 (Glt · K 2 ) 0.15 · 2H 2 O} n 1.62 g (3.35 mmol) of (NH 3 ) 2 PtI 2 , Ag 2
1.04 g (3.69 mmol) of SO 4 and [NP (OCH 3 )
(Glt · K 2 )] n 1.0 g (3.35 mmol) in Example 2
Reaction was carried out in the same manner as in Example 6 to obtain a polymer platinum complex compound.
【0076】 元素分析値(%): C, 15.8; H, 4.78; N, 10.6; P, 6.
36; Pt, 35.1 理論値(%) : C, 15.7; H, 3.97; N, 11.3; P, 6.
73; Pt, 36.0 水素核磁気共鳴スペクトル(D2O, ppm): 2.2(2H), 2.5(2
H), 3.4(3H), 3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 528(m), 619(m),
889(m), 1112(m), 1245(m), 1337(m), 1389(s), 1621
(s), 2948(m), 3241(s), 3354(s)Elemental analysis (%): C, 15.8; H, 4.78; N, 10.6; P, 6.
36; Pt, 35.1 Theoretical (%): C, 15.7; H, 3.97; N, 11.3; P, 6.
73; Pt, 36.0 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 2.2 (2H), 2.5 (2
H), 3.4 (3H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 528 (m), 619 (m),
889 (m), 1112 (m), 1245 (m), 1337 (m), 1389 (s), 1621
(s), 2948 (m), 3241 (s), 3354 (s)
【0077】実施例28{NP(OC2H5) 〔Glt・Pt(DACH)〕
0.8(Glt・K2)0.2 ・2H2O}n の合成 ポリジクロロホスファゼン3.0g 、L−グルタモイル
ジベンジルエステル−p−トルエンスルホン酸塩13.
6g(27.2mmol)及びエタノール50mlを反応させて
得た〔NP(OCH2 CH3)(L−Glt・K2)〕n
1.0g(3.19mmol)と、(DACH)PtI2 1.
80g(3.19mmol)及びAg2 SO4 0.99g(3.
19mmol)を実施例26と同様な方法で反応させ高分子
白金錯化合物を得た。Example 28 ΔNP (OC 2 H 5 ) [Glt · Pt (DACH)]
0.8 (Glt · K 2 ) Synthesis of 0.2 · 2H 2 O} n 3.0 g of polydichlorophosphazene, L-glutamoyl dibenzyl ester-p-toluenesulfonate 13.
[NP (OCH 2 CH 3 ) (L-Glt · K 2 )] n obtained by reacting 6 g (27.2 mmol) and 50 ml of ethanol.
1.0 g (3.19 mmol) and (DACH) PtI 2
80 g (3.19 mmol) and 0.99 g of Ag 2 SO 4 (3.
19 mmol) was reacted in the same manner as in Example 26 to obtain a polymer platinum complex compound.
【0078】 元素分析値(%): C, 27.7; H, 5.42; N, 9.01; P, 5.
31; Pt, 29.4 理論値(%) : C, 26.5; H, 4.9
4; N, 9.44; P, 5.80; Pt,
29.2 水素核磁気共鳴スペクトル(D2O, ppm):
1.1−1.3(7H), 1.6(2H), 2.0
(4H), 2.4(4H), 3.4(2H),
3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 518(m), 874(m),
964(m), 1033(m), 1065(m), 1124(m), 1173(m), 1245
(m), 1302(m), 1387(s), 2925(m), 3234(s), 3438(s)Elemental analysis (%): C, 27.7; H, 5.42; N, 9.01; P, 5.
31; Pt, 29.4 theoretical (%): C, 26.5; H, 4.9
4; N, 9.44; P, 5.80; Pt,
29.2 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm):
1.1-1.3 (7H), 1.6 (2H), 2.0
(4H), 2.4 (4H), 3.4 (2H),
3.8 (1H) infrared spectrum (KBr cell, cm -1 ): 518 (m), 874 (m),
964 (m), 1033 (m), 1065 (m), 1124 (m), 1173 (m), 1245
(m), 1302 (m), 1387 (s), 2925 (m), 3234 (s), 3438 (s)
【0079】実施例29{NP(NHCH3) 〔Glt・Pt(DACH)〕
0.8(Glt・K2)0.2 ・2H2O}n の合成 ポリジクロロホスファゼン3.0g 、L−グルタモイル
ジベンジルエステル−p−トルエンスルホン酸塩13.
6g(27.2mmol)及びメチルアミン(54.4mmol)
を反応させて得た〔NP(NHCH3)(L−Glt・K
2)〕n 1.0g(3.36mmol)と、(DACH)PtI
2 1.89g(3.36mmol)及びAg2SO4 1.05g
(3.36mmol)を実施例18と同様な方法で反応させ
高分子白金錯化合物を得た。Example 29 ΔNP (NHCH 3 ) [Glt · Pt (DACH)]
0.8 (Glt · K 2 ) Synthesis of 0.2 · 2H 2 O} n 3.0 g of polydichlorophosphazene, L-glutamoyl dibenzyl ester-p-toluenesulfonate 13.
6 g (27.2 mmol) and methylamine (54.4 mmol)
[NP (NHCH 3 ) (L-Glt · K
2 )] n 1.0 g (3.36 mmol) and (DACH) PtI
2 1.89 g (3.36 mmol) and Ag 2 SO 4 1.05 g
(3.36 mmol) was reacted in the same manner as in Example 18 to obtain a polymer platinum complex compound.
【0080】 元素分析値(%): C, 25.3; H, 5.53; N, 12.0; P, 5.
76; Pt, 30.1 理論値(%) : C, 25.0; H, 4.90; N, 12.4; P, 5.
98; Pt, 30.1 水素核磁気共鳴スペクトル(D2O, ppm): 1.1-1.3(4H),
1.6(2H), 2.0(2H), 2.5(5H), 3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 518(m), 614(m),
904(m), 1060(m), 1082(m), 1201(m), 1248(m), 1307
(m), 1403(s), 2938(m), 3194(s), 3418(s)Elemental analysis (%): C, 25.3; H, 5.53; N, 12.0; P, 5.
76; Pt, 30.1 Theoretical (%): C, 25.0; H, 4.90; N, 12.4; P, 5.
98; Pt, 30.1 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.1-1.3 (4H),
1.6 (2H), 2.0 (2H), 2.5 (5H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 518 (m), 614 (m),
904 (m), 1060 (m), 1082 (m), 1201 (m), 1248 (m), 1307
(m), 1403 (s), 2938 (m), 3194 (s), 3418 (s)
【0081】実施例30{NP(N(CH3)2) 〔 Glt・Pt(DAC
H) 〕0.8(Glt・K2)0.2 ・2H2O}n の合成 ポリジクロロホスファゼン3.0g 、L−グルタモイル
ジベンジルエステル−p−トルエンスルホン酸塩13.
6g(27.2mmol)、及びジメチルアミンヒドロクロリ
ド2.22g(27.2mmol)を反応させて得た〔NP
(N(CH3)2)(L−Glt・K2)〕n 1.0g(3.2
1mmol)と、(DACH)PtI2 1.81g(3.21
mmol)及びAg2 SO4 1.0g(3.21mmol)を実施
例29と同様な方法で反応させ高分子白金錯化合物を得
た。Example 30 ΔNP (N (CH 3 ) 2 ) [Glt · Pt (DAC
H)] 0.8 (Glt · K 2 ) 0.2 · 2H 2 O} n Synthesis of 3.0 g of polydichlorophosphazene, L-glutamoyl dibenzyl ester-p-toluenesulfonate 13.
6 g (27.2 mmol) and 2.22 g (27.2 mmol) of dimethylamine hydrochloride were reacted to obtain [NP
(N (CH 3 ) 2 ) (L-Glt · K 2 )] n 1.0 g (3.2
1 mmol) and 1.81 g (3.21 g) of (DACH) PtI 2.
mmol) and 1.0 g (3.21 mmol) of Ag 2 SO 4 were reacted in the same manner as in Example 29 to obtain a polymer platinum complex compound.
【0082】 元素分析値(%): C, 27.4; H, 5.80; N, 11.8; P, 5.
12; Pt, 29.0 理論値(%) : C, 26.6; H, 5.15; N, 12.1; P, 5.
82; Pt, 29.3 水素核磁気共鳴スペクトル(D2O, ppm): 1.1-1.3(4H),
1.6(2H), 2.0(4H), 2.4-2.6(10H), 3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 510(m), 625(m),
980(m), 1056(m), 1151(m), 1162(m), 1240(m), 1293
(m), 1397(s), 1628(s), 2923(m), 3198(s), 3432(s)Elemental analysis (%): C, 27.4; H, 5.80; N, 11.8; P, 5.
12; Pt, 29.0 Theoretical (%): C, 26.6; H, 5.15; N, 12.1; P, 5.
82; Pt, 29.3 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.1-1.3 (4H),
1.6 (2H), 2.0 (4H), 2.4-2.6 (10H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 510 (m), 625 (m),
980 (m), 1056 (m), 1151 (m), 1162 (m), 1240 (m), 1293
(m), 1397 (s), 1628 (s), 2923 (m), 3198 (s), 3432 (s)
【0083】実施例31{NP(OH)〔Am・Pt(DACH) 〕
0.9(Am・Na2)0.1 ・2H2O}n の合成 ポリジクロロホスファゼン3.0g 、ジエチルアミノマ
ロネートヒドロクロリド5.76g(27.2mmol)及び
H2 O 0.49ml(27.2mmol)を反応させて得た
〔NP(OH)(Am・Na2)〕n 1.0g(4.44mm
ol)と、(DACH)PtI2 2.50g(4.44mmo
l)及びAg2 SO4 1.38g(4.44mmol)を実施
例1と同様な方法で反応させ高分子白金錯化合物を得
た。Example 31 ΔNP (OH) [Am · Pt (DACH)]
Synthesis of 0.9 (Am · Na 2 ) 0.1 · 2H 2 O} n 3.0 g of polydichlorophosphazene, 5.76 g (27.2 mmol) of diethylaminomalonate hydrochloride and 0.49 ml (27.2 mmol) of H 2 O were reacted. [NP (OH) (Am.Na 2 )] n 1.0 g (4.44 mm)
ol) and 2.50 g (4.44 mmol) of (DACH) PtI 2
l) and 1.38 g (4.44 mmol) of Ag 2 SO 4 were reacted in the same manner as in Example 1 to obtain a polymer platinum complex compound.
【0084】 元素分析値(%): C, 19.4; H, 4.01; N, 9.82; P, 5.
88; Pt, 34.5 理論値(%) : C, 20.3; H, 3.91; N, 10.7; P, 6.
23; Pt, 35.3 水素核磁気共鳴スペクトル(D2O, ppm): 1.1-1.3(4H),
1.5(2H), 2.0(2H), 2.3(2H), 3.9(1H) 赤外線スペクトル(KBr cell, cm-1): 503(m), 775(m),
931(m), 1034(m), 1108(m), 1173(m), 1243(m), 1342
(s), 1453(m), 1641(s), 2923(m), 3208(s), 3414(s)Elemental analysis (%): C, 19.4; H, 4.01; N, 9.82; P, 5.
88; Pt, 34.5 Theoretical value (%): C, 20.3; H, 3.91; N, 10.7; P, 6.
23; Pt, 35.3 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.1-1.3 (4H),
1.5 (2H), 2.0 (2H), 2.3 (2H), 3.9 (1H) Infrared spectrum (KBr cell, cm -1 ): 503 (m), 775 (m),
931 (m), 1034 (m), 1108 (m), 1173 (m), 1243 (m), 1342
(s), 1453 (m), 1641 (s), 2923 (m), 3208 (s), 3414 (s)
【0085】実施例32{NP(OH)〔Am・Pt(CPA)2 〕
0.9(Am・Na2)0.1 ・2H2O}n の合成 (CPA)2PtI2 2.50g(4.44mmol)、Ag2
SO4 1.38g(4.44mmol)及び〔NP(OH)
(Am・Na2)〕n 1.0g(4.44mmol)を実施例3
1と同様な方法で反応させ高分子白金錯化合物を得た。Example 32 ΔNP (OH) [Am · Pt (CPA) 2 ]
Synthesis of 0.9 (Am · Na 2 ) 0.1 · 2H 2 O} n (CPA) 2 PtI 2 2.50 g (4.44 mmol), Ag 2
1.38 g (4.44 mmol) of SO 4 and [NP (OH)
(Am · Na 2 )] Example 3 was 1.0 g (4.44 mmol) of n.
Reaction was carried out in the same manner as in Example 1 to obtain a polymer platinum complex compound.
【0086】 元素分析値(%): C, 20.8; H, 4.31; N, 10.2; P, 6.
23; Pt, 33.9 理論値(%) : C, 20.3; H, 3.97; N, 10.7; P, 6.
23; Pt, 35.3 水素核磁気共鳴スペクトル(D2O, ppm): 0.8(8H), 2.3(2
H), 3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 534(m), 754(m),
931(m), 1043(m), 1182(m), 1210(m), 1394(s), 1654
(s), 2915(m), 3212(s), 3429(s)Elemental analysis (%): C, 20.8; H, 4.31; N, 10.2; P, 6.
23; Pt, 33.9 Theoretical value (%): C, 20.3; H, 3.97; N, 10.7; P, 6.
23; Pt, 35.3 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 0.8 (8H), 2.3 (2
H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 534 (m), 754 (m),
931 (m), 1043 (m), 1182 (m), 1210 (m), 1394 (s), 1654
(s), 2915 (m), 3212 (s), 3429 (s)
【0087】実施例33{NP(OH)〔Am・Pt(NH3)2 〕・2H2
O }n の合成 (NH3)2 PtI2 2.14g(4.44mmol)、Ag2
SO4 1.38g(4.44mmol)及び〔NP(OH)
(Am・Na2)〕n 1.0g(4.44mmol)を実施例3
1と同様な方法で反応させ高分子白金錯化合物を得た。Example 33 ΔNP (OH) [Am · Pt (NH 3 ) 2 ] · 2H 2
Synthesis of O} n (NH 3 ) 2 PtI 2 2.14 g (4.44 mmol), Ag 2
1.38 g (4.44 mmol) of SO 4 and [NP (OH)
(Am · Na 2 )] Example 3 was 1.0 g (4.44 mmol) of n.
Reaction was carried out in the same manner as in Example 1 to obtain a polymer platinum complex compound.
【0088】 元素分析値(%): C, 8.81; H, 3.31; N, 11.9; P, 7.
57; Pt, 43.1 理論値(%) : C, 8.63; H, 2.96; N, 12.6; P, 6.
99; Pt, 44.0 水素核磁気共鳴スペクトル(D2O, ppm): 3.8(1H) 赤外線スペクトル(KBr cell, cm-1): 518(m), 619(m),
976(m), 1072(m), 1176(m), 1334(m), 1386(s), 1632
(s), 2923(m), 3219(s), 3415(s)Elemental analysis (%): C, 8.81; H, 3.31; N, 11.9; P, 7.
57; Pt, 43.1 Theoretical (%): C, 8.63; H, 2.96; N, 12.6; P, 6.
99; Pt, 44.0 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ): 518 (m), 619 (m),
976 (m), 1072 (m), 1176 (m), 1334 (m), 1386 (s), 1632
(s), 2923 (m), 3219 (s), 3415 (s)
【0089】実施例34{NP(OCH3)〔Am・Pt(DACH) 〕
0.8(Am・Na2)0.2 ・2H2O}n の合成 ポリジクロロホスファゼン3.0g 、ジエチルアミノマ
ロネートヒドロクロリド5.76g(27.2mmol)及び
メタノール50mlを反応させて得た〔NP(OCH3)
(Am・Na2)〕n 1.0g(4.18mmol)と、(DA
CH)PtI2 2.35g(4.18mmol)及びAg2 S
O4 1.30g(4.18mmol)を実施例13と同様な方
法で反応させ高分子白金錯化合物を得た。Example 34 ΔNP (OCH 3 ) [Am · Pt (DACH)]
Synthesis of 0.8 (Am · Na 2 ) 0.2 · 2H 2 O} n 3.0 g of polydichlorophosphazene, 5.76 g (27.2 mmol) of diethylaminomalonate hydrochloride and 50 ml of methanol were reacted to obtain NP (OCH 3 )
(Am · Na 2 )] n (1.0 g, 4.18 mmol) and (DA
CH) PtI 2 2.35 g (4.18 mmol) and Ag 2 S
1.30 g (4.18 mmol) of O 4 was reacted in the same manner as in Example 13 to obtain a polymer platinum complex compound.
【0090】 元素分析値(%): C, 21.5; H, 4.31; N, 9.72; P, 5.
90; Pt, 31.6 理論値(%) : C, 21.8; H, 4.20; N, 10.4; P, 6.
39; Pt, 32.2 水素核磁気共鳴スペクトル(D2O, ppm):
1.1−1.3(4H), 1.5(2H), 2.0
(2H), 2.3(2H), 3.4(3H),
3.8(1H) 赤外線スペクトル(KBr cell, cm−1):
507(m), 775(m), 931(m),
1071(m), 1033(m), 1162
(m), 1248(m), 1323(s), 16
51(s), 2930(m), 3202(s),
3428(s)Elemental analysis (%): C, 21.5; H, 4.31; N, 9.72; P, 5.
90; Pt, 31.6 Theoretical value (%): C, 21.8; H, 4.20; N, 10.4; P, 6.
39; Pt, 32.2 hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm):
1.1-1.3 (4H), 1.5 (2H), 2.0
(2H), 2.3 (2H), 3.4 (3H),
3.8 (1H) infrared spectrum (KBr cell, cm -1 ):
507 (m), 775 (m), 931 (m),
1071 (m), 1033 (m), 1162
(M), 1248 (m), 1323 (s), 16
51 (s), 2930 (m), 3202 (s),
3428 (s)
【0091】実施例35{NP(OCH3)〔Am・Pt(NH3)2 〕
0.85(Am・Na2)0.15・2H2O }n の合成 (NH3)2 PtI2 2.02g(4.18mmol)、Ag2
SO4 1.30g(4.18mmol)及び〔NP(OCH3)
(Am・Na2)〕n 1.0g(4.18mmol)を実施例2
6と同様な方法で反応させ高分子白金錯化合物を得た。Example 35 ΔNP (OCH 3 ) [Am · Pt (NH 3 ) 2 ]
Synthesis of 0.85 (Am · Na 2 ) 0.15 · 2H 2 O} n (NH 3 ) 2 PtI 2 2.02 g (4.18 mmol), Ag 2
1.30 g (4.18 mmol) of SO 4 and [NP (OCH 3 )
(Am.Na 2 )] Example 2 was prepared using 1.0 g (4.18 mmol) of n.
Reaction was carried out in the same manner as in Example 6 to obtain a polymer platinum complex compound.
【0092】 元素分析値(%): C, 12.0; H, 3.81; N, 11.5; P, 6.
69; Pt, 37.9 理論値(%) : C, 11.2; H, 3.33; N, 12.1; P, 7.
25; Pt, 38.8 水素核磁気共鳴スペクトル(D2O, ppm): 3.3(3H), 3.8(1
H) 赤外線スペクトル(KBr cell, cm-1): 507(m), 614(m),
714(m), 920(m), 1032(m), 1074(m), 1186(m), 1234
(m), 1387(s), 1443(m), 1636(s), 2932(m), 3251(s),
3421(s)Elemental analysis (%): C, 12.0; H, 3.81; N, 11.5; P, 6.
69; Pt, 37.9 theoretical (%): C, 11.2; H, 3.33; N, 12.1; P, 7.
25; Pt, 38.8 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 3.3 (3H), 3.8 (1
H) Infrared spectrum (KBr cell, cm -1 ): 507 (m), 614 (m),
714 (m), 920 (m), 1032 (m), 1074 (m), 1186 (m), 1234
(m), 1387 (s), 1443 (m), 1636 (s), 2932 (m), 3251 (s),
3421 (s)
【0093】実施例36{NP(NHCH3) 〔Am・Pt(DACH) 〕
0.8(Am・Na2)0.2・2H2O }n の合成 ポリジクロロホスファゼン3.0g 、ジエチルアミノマ
ロネートヒドロクロリド5.76g(27.2mmol)及び
メチルアミン54.4mmolを反応させて得た〔NP(N
HCH3)(Am・Na2)〕n 1.0g(4.20mmol)
と、(DACH)PtI2 2.36g(4.20mmol)及
びAg2 SO4 1.31g(4.20mmol)を実施例18
と同様な方法で反応させ高分子白金錯化合物を得た。Example 36 ΔNP (NHCH 3 ) [Am · Pt (DACH)]
Synthesis of 0.8 (Am · Na 2 ) 0.2 · 2H 2 O} n 3.0 g of polydichlorophosphazene, 5.76 g (27.2 mmol) of diethylaminomalonate hydrochloride and 54.4 mmol of methylamine were obtained by reacting [NP (N
HCH 3 ) (Am · Na 2 )] n 1.0 g (4.20 mmol)
And 2.36 g (4.20 mmol) of (DACH) PtI 2 and 1.31 g (4.20 mmol) of Ag 2 SO 4 in Example 18.
The reaction was carried out in the same manner as in the above to obtain a polymer platinum complex compound.
【0094】 元素分析値(%): C, 23.1; H, 4.31; N, 12.6; P, 5.
83; Pt, 31.9 理論値(%) : C, 21.8; H, 4.42; N, 13.3; P, 6.
40; Pt, 32.3 水素核磁気共鳴スペクトル(D2O, ppm): 1.1-1.3(4H),
1.5(2H), 2.0(2H), 2.3(2H), 2.6(3H), 3.8(1H) 赤外線スペクトル(KBr cell, cm−1):
518(m), 609(m), 765(m),
1119(m), 1259(m), 1318
(m), 1323(s), 1447(m), 16
61(m), 2912(m), 3224(s),
3396(s)Elemental analysis (%): C, 23.1; H, 4.31; N, 12.6; P, 5.
83; Pt, 31.9 Theoretical value (%): C, 21.8; H, 4.42; N, 13.3; P, 6.
40; Pt, 32.3 Hydrogen nuclear magnetic resonance spectrum (D 2 O, ppm): 1.1-1.3 (4H),
1.5 (2H), 2.0 (2H), 2.3 (2H), 2.6 (3H), 3.8 (1H) Infrared spectrum (KBr cell, cm -1 ):
518 (m), 609 (m), 765 (m),
1119 (m), 1259 (m), 1318
(M), 1323 (s), 1447 (m), 16
61 (m), 2912 (m), 3224 (s),
3396 (s)
【0095】〔抗ガン活性試験〕本発明の高分子白金錯
化合物に関する抗ガン活性試験を、標準方法(Gold
in他, Europ. J. Cancer, 17, 129(1981))により次の
ように行った。6ないし8週齢の実験用マウス(BDF
1マウス)8匹を一群にして、マウス1匹当たり106
個のマウス白血病細胞L1210を移植した。本発明に
よる白金錯化合物を0.9%生理食塩水に溶解し、必要
に応じて30〜60mg/kg を腹腔内注射(i.p.)により
第1、5、9日に投与した後、平均寿命延長時間(IL
S:Increased Life Span 、%)と60日後の生存匹数
を調査した。対照化合物としては既存のシスプラチンを
用いた。[Anti-Cancer Activity Test] The anti-cancer activity test for the polymer platinum complex compound of the present invention was carried out by a standard method (Gold
In et al., Europ. J. Cancer, 17, 129 (1981)). 6-8 week old experimental mice (BDF
(1 mouse) 8 animals in one group, 10 6
Each mouse leukemia cell L1210 was transplanted. The platinum complex compound of the present invention is dissolved in 0.9% physiological saline, and if necessary, 30 to 60 mg / kg is administered by intraperitoneal injection (ip) on the first, fifth and ninth days. Time (IL
S: Increased Life Span,%) and the number of surviving animals after 60 days were examined. Existing cisplatin was used as a control compound.
【0096】その結果を表1に示した。本発明の高分子
白金錯化合物の抗ガン活性がシスプラチンやカルボプラ
チンより極めて優れていることがわかる。Table 1 shows the results. It can be seen that the anticancer activity of the polymer platinum complex of the present invention is extremely superior to cisplatin and carboplatin.
【0097】また、急性毒性についても、本発明の代表
的化合物である実施例1の化合物のLD50(160mg/k
g)及び実施例21の化合物のLD50(130mg/kg)は、
シスプラチンのLD50(13mg/kg)より遥かに大きく、
カルボプラチンのLD50(180mg/kg)と類似してお
り、第3世代抗ガン剤として開発される可能性が非常に
高いことがわかる。Also, regarding acute toxicity, the LD 50 (160 mg / k) of the compound of Example 1 which is a representative compound of the present invention was used.
g) and the LD 50 of the compound of Example 21 (130 mg / kg)
Much larger than the LD 50 of cisplatin (13 mg / kg)
It is similar to the LD 50 of carboplatin (180 mg / kg), indicating that the possibility of development as a third generation anticancer drug is very high.
【0098】[0098]
【表1】 [Table 1]
フロントページの続き (72)発明者 趙 良 河 大韓民国ソウル特別市蘆原区上渓1洞 1110 上渓再開發住公アパート103− 1105 (72)発明者 鄭 玉 相 大韓民国ソウル特別市道峰区雙門洞56 三益アパート105−706 (56)参考文献 特開 昭56−30430(JP,A) 特開 昭53−115691(JP,A) 米国特許3893980(US,A) 米国特許5104947(US,A) 国際公開97/12891(WO,A) BULL.KOREAN CHEM. SOC.,16〜11! (1995) P. 1074−1079 (58)調査した分野(Int.Cl.6,DB名) C08G 79/02 - 79/06 A61K 31/80 C07F 15/00 CA(STN) REGISTRY(STN)Continuing on the front page (72) Inventor Zhao Ryohe 1110 Sangye 1-dong, Sowon-gu, Seoul, Republic of Korea 10310 Reopening of Sangye Apartment 103-1105 Mondong 56 Sanmasu apartment 105-706 (56) References JP-A-56-30430 (JP, A) JP-A-53-115691 (JP, A) US Patent 3,893,980 (US, A) US Patent 5,104,947 (US, A) ) WO 97/12891 (WO, A) BULL. KOREAN CHEM. SOC. , 16 ~ 11! (1995) P. 1074-1079 (58) Fields investigated (Int. Cl. 6 , DB name) C08G 79/02-79/06 A61K 31/80 C07F 15/00 CA (STN) REGISTRY (STN)
Claims (11)
錯化合物。 【化1】 〔式中、高分子骨格は、P=N反復単位を有するポリホ
スファゼンを基体とし、 Sは、溶解性を付与する基であって、ヒドロキシル基、
アルコキシ基、又はアルキルアミノ基を示し; Aは、一座中性リガンドのアンモニア、又は1〜3個の
炭素原子を有するアルキルアミンもしくはシクロプロピ
ルアミン(CPA)を示すか、あるいはエチレンジアミ
ン(en)、プロピレンジアミン(pn)、2−ヒドロ
キシ−1,3−ジアミノプロパン(HDAP)、2,2
−ジメチル−1,3−ジアミノプロパン(DMDA
P)、1,1−ジアミノメチルシクロブタン(DAMC
B)、テトラヒドロ−4H−ピラン−4,4−ジメタン
アミン(THPDMA)、2,2−ビスアミノメチル−
1,3−プロパンジオール(BAMPDO)及びトラン
ス−1,2−ジアミノシクロヘキサン(DACH)から
選ばれる2個のアミンが一緒になったA−A型のキレー
ト型アミンを形成し; xは、整数0、1又は2を示し、アミノジカルボン酸の
陰イオン部分は、アミノジカルボン酸の種類に応じて、
x=0のときはアミノマロン酸(Am)誘導体、x=1
のときはアスパラギン酸(Asp)誘導体、x=2のと
きはグルタミン酸(Glt)誘導体を示し; Mは、2個のアルカリ金属イオン又は2個のアンモニウ
ムイオンを示すか、あるいは1個のアルカリ土類金属イ
オンを示し; 白金錯体の含量を示すm値は、0.2ないし1であり、
ポリホスファゼンの重合度を示すn値は、10ないし1
00である。〕1. A high-molecular platinum complex compound represented by the following general formula (I). Embedded image Wherein the polymer skeleton is based on a polyphosphazene having P = N repeating units, and S is a group that imparts solubility, and is a hydroxyl group,
A represents an alkoxy group or an alkylamino group; A represents a monodentate neutral ligand, ammonia, or an alkylamine or cyclopropylamine (CPA) having 1 to 3 carbon atoms, or ethylenediamine (en), propylene Diamine (pn), 2-hydroxy-1,3-diaminopropane (HDAP), 2,2
-Dimethyl-1,3-diaminopropane (DMDA
P), 1,1-diaminomethylcyclobutane (DAMC
B), tetrahydro-4H-pyran-4,4-dimethanamine (THPDMA), 2,2-bisaminomethyl-
Two amines selected from 1,3-propanediol (BAMPDO) and trans-1,2-diaminocyclohexane (DACH) are combined to form an AA type chelating amine; x is an integer 0 Represents 1 or 2, the anionic portion of the aminodicarboxylic acid, depending on the type of aminodicarboxylic acid,
When x = 0, aminomalonic acid (Am) derivative, x = 1
Represents an aspartic acid (Asp) derivative, x = 2 represents a glutamic acid (Glt) derivative; M represents two alkali metal ions or two ammonium ions, or one alkaline earth ion M value indicating the content of the platinum complex is 0.2 to 1,
The n value indicating the degree of polymerization of polyphosphazene is 10 to 1
00. ]
子白金錯化合物。2. The polymer platinum complex compound according to claim 1, wherein the m value is 1.
合物連結剤であるアミノジカルボン酸誘導体と溶解性を
付与する基を導入した後、加水分解工程を経て得られる
一般式(II)のアンモニウム塩もしくはアルカリ金属塩
又は一般式(III)のアルカリ土類金属塩を、一般式(I
V)のジアミン白金酸性塩と1:0.2〜1のモル比
で、常温の水溶液中で反応させることを特徴とする、請
求項1に記載の一般式(I)の高分子白金錯化合物の製
造方法。 【化2】 〔上記式中、S、A、x、M、m及びnは、前記で定義
されたとおりであり、M(I)は、アンモニウムイオン
又はアルカリ金属イオンを示し、M(II)は、アルカリ
土類金属イオンを示し、X2 は、陰イオンであって、2
個のNO3 -イオン、又は1個のSO4 2- イオンを示
す。〕3. An ammonium salt or an alkali salt of the general formula (II) obtained by introducing into a polydichlorophosphazene an aminodicarboxylic acid derivative as a platinum complex compound linking agent and a group imparting solubility, and then subjecting the compound to a hydrolysis step. A metal salt or an alkaline earth metal salt of the general formula (III)
The polymer platinum complex compound of the general formula (I) according to claim 1, characterized in that it is reacted with an acidic salt of diamine platinum of V) at a molar ratio of 1: 0.2 to 1 in an aqueous solution at room temperature. Manufacturing method. Embedded image [Wherein, S, A, x, M, m and n are as defined above, M (I) represents an ammonium ion or an alkali metal ion, and M (II) represents an alkaline earth X 2 represents an anion and represents 2
Number of NO 3 - shows ion, or one SO 4 2-ions. ]
一般式(III)のアルカリ土類金属塩を、一般式(IV)の
ジアミン白金酸性塩と1:1のモル比で反応させる、請
求項3に記載の高分子白金錯化合物の製造方法。4. The alkali metal salt of the general formula (II) or the alkaline earth metal salt of the general formula (III) is reacted with the diamine platinum acid salt of the general formula (IV) in a molar ratio of 1: 1. A method for producing the polymer platinum complex compound according to claim 3.
ロン酸、アスパラギン酸及びグルタミン酸のメチルエス
テル、エチルエステル、ベンジルエステル及びアルキル
アミドから選ばれ;溶解性を付与する基が、ヒドロキシ
ル基、又はメトキシ、エトキシ及び(2−メトキシ)エ
トキシから選ばれるアルコキシ基、又はメチルアミノ及
びジメチルアミノから選ばれる水溶性アルキルアミノ基
である、請求項3に記載の高分子白金錯化合物の製造方
法。5. The aminodicarboxylic acid derivative is selected from aminomalonic acid, aspartic acid and glutamic acid methyl ester, ethyl ester, benzyl ester and alkylamide; and the group imparting solubility is a hydroxyl group, methoxy, ethoxy, The method for producing a polymer platinum complex compound according to claim 3, wherein the compound is an alkoxy group selected from (2) and (2-methoxy) ethoxy, or a water-soluble alkylamino group selected from methylamino and dimethylamino.
ムであり、アルカリ土類金属が、バリウム又はカルシウ
ムであり、一般式(IV)のジアミン白金酸性塩が、ジア
ミン白金硫酸塩又はジアミン白金硝酸塩である、請求項
3に記載の高分子白金錯化合物の製造方法。6. The alkali metal is sodium or potassium, the alkaline earth metal is barium or calcium, and the diamine platinum acid salt of the general formula (IV) is diamine platinum sulfate or diamine platinum nitrate. A method for producing the polymer platinum complex compound according to claim 3.
(IV)のジアミン白金(II)硫酸塩とを、常温の水溶液
中で1:0.2〜1のモル比で反応させた後、反応混合
物を濃縮してから有機溶媒を加える、請求項6に記載の
高分子白金錯化合物の製造方法。7. An alkali metal salt of the general formula (II) and a diamineplatinum (II) sulfate of the general formula (IV) are reacted at a molar ratio of 1: 0.2 to 1 in an aqueous solution at room temperature. The method for producing a polymer platinum complex compound according to claim 6, wherein the organic solvent is added after concentrating the reaction mixture.
タノール及びエチルエーテルから選ばれる単独溶媒又は
二種以上の溶媒である、請求項7に記載の高分子白金錯
化合物の製造方法。8. The method according to claim 7, wherein the organic solvent is a single solvent selected from acetone, ethanol, methanol, and ethyl ether, or two or more solvents.
(IV)のジアミン白金(II)硝酸塩とを、常温の水溶液
中で1:0.2〜1モル比で反応させた後、半透膜(分
子量1,000以下通過)を用いて透析する、請求項6
に記載の高分子白金錯化合物の製造方法。9. An alkali metal salt of the general formula (II) and a diamineplatinum (II) nitrate of the general formula (IV) are reacted in an aqueous solution at room temperature in a molar ratio of 1: 0.2 to 1; 7. Dialysis using a semipermeable membrane (passing a molecular weight of 1,000 or less).
3. The method for producing a polymer platinum complex compound according to item 1.
(IV)のジアミン白金(II)硝酸塩とを、常温の水溶液
中で1:0.2〜1のモル比で反応させ、硫酸バリウム
を沈殿として取り除く、請求項6に記載の高分子白金錯
化合物の製造方法。10. A barium sulfate of the formula (III) is reacted with a diamineplatinum (II) nitrate of the formula (IV) in an aqueous solution at room temperature in a molar ratio of 1: 0.2 to 1; 7. The method for producing a polymer platinum complex compound according to claim 6, wherein the compound is removed as a precipitate.
子白金錯化合物を有効成分とする抗ガン剤。11. An anticancer agent comprising the polymer platinum complex compound of the general formula (I) according to claim 1 or 2 as an active ingredient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019950033694A KR0164460B1 (en) | 1995-10-02 | 1995-10-02 | Polymer-pt coordination compound process for preparation and the anti-cancers using it |
KR33694/1995 | 1995-10-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09110996A JPH09110996A (en) | 1997-04-28 |
JP2749295B2 true JP2749295B2 (en) | 1998-05-13 |
Family
ID=19429058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8004602A Expired - Fee Related JP2749295B2 (en) | 1995-10-02 | 1996-01-16 | High-molecular platinum complex compound, method for producing the same, and anticancer agent containing the same as an active ingredient |
Country Status (5)
Country | Link |
---|---|
US (1) | US5665343A (en) |
JP (1) | JP2749295B2 (en) |
KR (1) | KR0164460B1 (en) |
AU (1) | AU4316696A (en) |
WO (1) | WO1997012891A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965118A (en) * | 1997-04-18 | 1999-10-12 | Access Pharmaceuticals, Inc. | Polymer-platinum compounds |
US6113934A (en) * | 1998-06-11 | 2000-09-05 | Virginia Commonwealth University | Platinum complexes with anti-viral activity and method of using same |
KR100314720B1 (en) * | 1999-03-26 | 2001-11-26 | 박호군 | Platinum complex conjugated to cyclotriphosphazene, prepration thereof, and anticancer agent comprising the same |
WO2001024763A2 (en) | 1999-10-01 | 2001-04-12 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US7166733B2 (en) * | 2000-01-04 | 2007-01-23 | Access Pharmaceuticals, Inc. | O,O'-Amidomalonate and N,O-Amidomalonate platinum complexes |
KR100729015B1 (en) | 2000-01-04 | 2007-06-14 | 어섹스 팔마큐티칼스 인코포레이티드 | N,o-amidomalonate platinum complexes |
KR100363394B1 (en) * | 2000-08-21 | 2002-12-05 | 한국과학기술연구원 | Temperature-sensitive cyclotriphosphazene-platinum complex, its preparation method and anticancer agent containing the same |
KR100499340B1 (en) * | 2003-04-29 | 2005-07-04 | 학교법인 이화학당 | Tumor selective and biodegradable polyphosphazene-platinum(ⅱ) conjugate anticancer agent, and preparation method thereof |
EP1874729B1 (en) * | 2005-04-15 | 2011-11-16 | Parallel Solutions, Inc. | Biodegradable polyphosphazenes containing pyrrolidone side groups |
KR100784485B1 (en) | 2006-01-18 | 2007-12-11 | 한국과학기술연구원 | Biodegradable and thermosensitive polyorganophosphazene hydrogel, preparation method thereof and use thereof |
KR100943923B1 (en) * | 2006-03-17 | 2010-02-24 | 홍순해 | Composition and methods regarding the design and development of non-toxic and global anticancer drug that is achieved through organometallic nanoparticles with biologically active matals and enhanced permeation and retention effect |
KR100746962B1 (en) * | 2006-04-04 | 2007-08-07 | 한국과학기술연구원 | Thermosensitive polyphosphazene-bioactive molecule conjugates, preparation method thereof and use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4151185A (en) * | 1977-05-02 | 1979-04-24 | Research Corporation | Complex or salt of a platinum (II) compound and a nitrogen containing polymer |
US4284579A (en) * | 1979-07-17 | 1981-08-18 | The United States Of America As Represented By The Of The Department Of Health & Human Services | (N-Phosphonacetyl-L-aspartato)(1,2-diaminocyclchexane)platinum(II) or alkali metal salt |
US4882447A (en) * | 1987-02-20 | 1989-11-21 | Tanabe Seiyaku Co., Ltd. | Novel organic platinum complex and process for the preparation thereof |
FI87572C (en) * | 1987-05-08 | 1993-01-25 | Sankyo Co | Process for the preparation of platinum complexes with therapeutic effect |
US4931553A (en) * | 1988-05-11 | 1990-06-05 | Gill Devinder S | Platinum-polymer complexes and their use as antitumor agents |
US5104947A (en) * | 1989-08-07 | 1992-04-14 | Ethyl Corporation | Polyphosphazenes and their synthesis |
-
1995
- 1995-10-02 KR KR1019950033694A patent/KR0164460B1/en not_active IP Right Cessation
- 1995-12-26 AU AU43166/96A patent/AU4316696A/en not_active Abandoned
- 1995-12-26 WO PCT/KR1995/000172 patent/WO1997012891A1/en active Application Filing
-
1996
- 1996-01-02 US US08/582,557 patent/US5665343A/en not_active Expired - Fee Related
- 1996-01-16 JP JP8004602A patent/JP2749295B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
BULL.KOREAN CHEM. SOC.,16〜11! (1995) P.1074−1079 |
Also Published As
Publication number | Publication date |
---|---|
KR0164460B1 (en) | 1999-03-20 |
US5665343A (en) | 1997-09-09 |
KR970021085A (en) | 1997-05-28 |
JPH09110996A (en) | 1997-04-28 |
AU4316696A (en) | 1997-04-28 |
WO1997012891A1 (en) | 1997-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2749295B2 (en) | High-molecular platinum complex compound, method for producing the same, and anticancer agent containing the same as an active ingredient | |
JPH0244838B2 (en) | ||
JP5201572B2 (en) | Method for producing polymerized coordination compound of platinum complex | |
EP0111388B1 (en) | Therapeutic compounds of platinum and palladium and their preparation | |
JPS6013795A (en) | Diaminocyclohexane platinium complex | |
RU2130941C1 (en) | Trinuclear cationic platinum complexes having antitumor activity, method of preparing thereof, and pharmaceutical compositions containing said complexes | |
JP3677269B2 (en) | Temperature-sensitive cyclotriphosphazene-platinum complex, method for producing the same, and anticancer agent composition containing the same | |
EP0163316B1 (en) | Platinum-intercalative complexes for the treatment of cancer | |
KR100314720B1 (en) | Platinum complex conjugated to cyclotriphosphazene, prepration thereof, and anticancer agent comprising the same | |
US4234499A (en) | Cis-diammireplatinum(II) organophosphate complexes | |
JP2000506855A (en) | Binuclear platinum complex, method for preparing the same, and pharmaceutical composition containing the complex | |
EP0270682A1 (en) | Novel complexes, process for their preparation, and medicinal use of them | |
US4291023A (en) | Method for treating tumors using cis-diammineplatinum (II) organophosphate complexes | |
Yoo et al. | Synthesis of stable platinum complexes containing carborane in a carrier group for potential BNCT agents | |
CN111808141A (en) | Method for efficiently preparing lobaplatin anhydride | |
KR890004351B1 (en) | Process for the preparation of anti-tumor platinum complexs | |
CN110423253A (en) | A kind of platinum complex of the base containing single silane and its application | |
WO2003045962A1 (en) | Supermolecular carboplatinum derivatives, their preparation and pharmaceutical composition containing them as active ingredient and applications of the compositions | |
EP0261044A2 (en) | Novel platinum-riboflavin-complexes | |
JPH0523276B2 (en) | ||
KR910009822B1 (en) | Process for the preparation of platinum complexes | |
JPS63258890A (en) | Platinum urea complex | |
JPH02212497A (en) | Novel platinum complex and production thereof | |
EP0386243A1 (en) | Platinum (ii) complexes | |
JPS6344591A (en) | Production of platinum green complex |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Cancellation because of no payment of annual fees |